Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒x No ☐o

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒x No ☐o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

☐o

Accelerated filer

☒x

Non-accelerated filer

☐o

Smaller reporting company

x☒

Emerging growth company

☒x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐o No ☒x

As of February ~~6, 2023,~~5, 2024, there were ~~135,596,225~~135,899,435 of the registrant’s common stock outstanding.

InnovAge Holding Corp. and Subsidiaries

Quarterly Report on Form 10-Q

For the quarterly period ended December 31, ~~2022~~

2023

Cautionary Note on Forward-Looking Statements

Throughout this Quarterly Report on Form 10-Q, we make “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements describe future expectations, plans, results or strategies and can often be identified by the use of terminology such as “may,” “will,” “estimate,” “intend,” “plan,” “continue,” “believe,” “expect,” “anticipate,” “target,” “should,” “could,” “potential,” “opportunity,” “goal” or similar terminology. All statements other than statements of historical fact included in this Quarterly Report on Form 10-Q are forward-looking statements. Forward-looking statements ~~may be identified by the fact that they do not relate strictly~~give our current expectations and projections relating to ~~historical or current facts~~our financial condition, results of operations, plans, objectives, future performance and ~~may include statements about our expectations~~business, including with respect to current audits and legal proceedings and actions, relationships and discussions with regulatory agencies, our expectations with respect to correcting deficiencies raised in audits and other processes, and our expectations to increase the number of participants we serve, to grow enrollment and capacity within existing centers, to build or open de novo centers, and other similar statements. The forward-looking statements contained in this Quarterly Report on Form 10-Q are generally located ~~in the material set forth~~ under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” included in Part I, Item 2, and “Risk Factors,” included in Part II, Item 1A, but may be found in other locations as well. These statements are based upon management’s current expectations, projections, assumptions and estimates and are not guarantees of timing, future results or performance. Therefore, you should not rely on any of these forward-looking statements as predictions of future events. Actual results may differ materially from those contemplated in these statements due to a variety of risks and uncertainties and other factors, including, among other things:

●

the results of periodic inspections, reviews, audits and investigations under the federal and state government programs, including the sanctions currently in place on our Sacramento center in California and our ability to sufficiently cure any deficiencies identified by the respective federal and state government programs including with respect to the audits of our Albuquerque, New Mexico center and San Bernardino, California center;

●

the adverse impact of inspections, reviews, audits, investigations, legal proceedings, enforcement actions and litigation, including the current civil investigative demands initiated by federal and state agencies, as well as the litigation and other proceedings initiated by, or on behalf, of our stockholders;

●

~~the effects of a pandemic, epidemic or outbreak of an infectious disease, including the ongoing effects of COVID-19;~~

●

~~the risk that the cost of providing services will exceed our compensation under the Program of All Inclusive Care for the Elderly (“PACE”);~~

●

~~the dependence of our revenues and operations upon a limited number of government payors;~~

●

~~changes in the rules governing the Medicare, Medicaid or PACE programs or applicable licensure requirements;~~

●

~~the risk that our submissions to government payors may contain inaccurate or unsupportable information, including regarding risk adjustment scores of participants;~~

●

~~the viability of our business strategy and our ability to realize expected results;~~

●

~~the impact on our business of renegotiation, non-renewal or termination of capitation agreements with government payors;~~

●

~~the impact of state and federal efforts to reduce healthcare spending;~~

●

~~the impact on our business from an economic downturn~~

●

~~our dependence on our senior management team and other key employees;~~

●

~~the effect of sustained inflation on our business;~~

●

~~the impact of failures by our suppliers, sustained material price increases on supplies or limitations on our ability to access new technology or medical products;~~

●

~~the effect of our relatively limited operating history as a for-profit company on investors’ ability to evaluate our current business and future prospects;~~

●

~~our ability to enroll or attract new participants and grow our revenue, especially as a result of the sanctions currently in place on our Sacramento center in California and actions from other states;~~

•our ability to identify and successfully complete and integrate acquisitions;

•our ability to attract new participants and retain existing participants and grow our revenue throughout our existing centers;

•the results of periodic inspections, reviews, audits and investigations under the federal and state government programs, such as the audit of our Sacramento, California center and the targeted medical review of our San Bernardino, California center, and our ability to sufficiently cure any new and recurring deficiencies identified by the respective federal and state government programs;

•the adverse impact of inspections, reviews, audits, investigations, legal proceedings, enforcement actions and litigation, including the current civil investigative demands initiated by federal and state agencies, as well as the litigation and other proceedings initiated by, or on behalf, of our stockholders;

•the risk that the cost of providing services will exceed our compensation under the Program of All Inclusive Care for the Elderly (“PACE”);

•our increased costs and expenditures in the future and our inability to execute or realize the benefits of our clinical value initiatives;

•the impact on our business from ongoing macroeconomic related challenges, including labor shortages and inflation;

•the dependence of our revenues and operations upon a limited number of government payors;

•the risk that our submissions to government payors may contain inaccurate or unsupportable information, including regarding risk adjustment scores of participants;

•the impact on our business of renegotiation, non-renewal or termination of capitation agreements with government payors;

•the difficulty to predict our future results, which could cause such results to fall below any guidance we provide;

•the impact of state and federal efforts to reduce healthcare spending;

•the effects of a pandemic, epidemic or outbreak of an infectious disease, such as COVID-19;

•our dependence on our senior management team and other key employees;

•the impact of failures by our suppliers or limitations on our ability to access new technology or medical products;

•the concentration of our presence in Colorado;

•our ability to manage our operations effectively, execute our business plan, maintain effective levels of service and participant satisfaction and adequately address competitive challenges;

•our ability to compete in the healthcare industry;

•our ability to establish a presence in new geographic markets;

•the impact of competition for physicians and other clinical personnel and related increases in our labor costs;

●

~~the concentration of our presence in Colorado;~~

●

~~our ability to manage our operations effectively, execute our business plan, maintain effective levels of service and participant satisfaction and adequately address competitive challenges;~~

●

~~our ability to compete in the healthcare industry;~~

●

~~our ability to establish a presence in new geographic markets, especially as a result of the actions taken by certain states and us in light of our ongoing audit processes;~~

●

~~the impact of competition for physicians and other clinical personnel and related increases in our labor costs;~~

●

~~the impact on our business of security breaches, loss of data or other disruptions causing the compromise of sensitive information or preventing us from accessing critical information;~~

●

~~our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems;~~

●

~~our ability to accurately estimate incurred but not reported medical expense or the risk scores of our participants;~~

●

~~risks associated with our use of “open-source” software;~~

●

~~the impact on our business of the termination of our leases, increases in rent or inability to renew or extend leases;~~

●

~~our ability to maintain our corporate culture;~~

●

~~the impact of negative publicity regarding the managed healthcare industry;~~

●

~~the impact of weather and other factors beyond our control;~~

●

our ability to adhere to complex and changing government laws and regulations in the healthcare industry, including U.S. Healthcare reform, the regulation of the corporate practice of medicine and the Health Information Technology for Economic and Clinical Health Act of 2009 (the “HITECH Act”), and their implementing regulations (collectively, “HIPAA”), the California Consumer Privacy Act (“CCPA”) and other privacy laws and regulations in the healthcare industry;

●

~~our status as a “controlled company”;~~

●

~~our ability to maintain effective internal controls over financial reporting and other enhanced requirements of being a public company;~~

●

~~our ability to maintain and enhance our reputation and brand recognition;~~

●

~~the impact on our business of disruptions in our disaster recovery systems or business continuity planning;~~

●

~~changes in accounting principles and guidance, resulting in unfavorable accounting charges or effects; and~~

•labor relations matters, including unionization efforts;

●•the impact on our business of security breaches, loss of data or other disruptions causing the compromise of sensitive information or preventing us from accessing critical information;

•our ability to effectively invest in, implement improvements to and properly maintain the uninterrupted operation and data integrity of our information technology and other business systems;

•our ability to accurately estimate incurred but not reported medical expense or the risk scores of our participants;

•risks associated with our use of “open-source” software;

•the impact on our business of the termination of our leases, increases in rent or inability to renew or extend leases;

•the impact of weather and other factors beyond our control;

•the effect of our relatively limited operating history as a for-profit company on investors' ability to evaluate our current business and future prospects;

•our ability to adhere to complex and changing government laws and regulations in the healthcare industry, including U.S. Healthcare reform, the regulation of the corporate practice of medicine and the Health Information Technology for Economic and Clinical Health Act of 2009 (the “HITECH Act”), and their implementing regulations (collectively, “HIPAA”), the California Consumer Privacy Act (“CCPA”) and other privacy laws and regulations in the healthcare industry;

•our status as a “controlled company”;

•our ability to maintain effective internal controls over financial reporting and other enhanced requirements of being a public company;

•our ability to maintain and enhance our reputation and brand recognition;

•the impact on our business of disruptions in our disaster recovery systems or business continuity planning;

•impact of negative publicity regarding the managed healthcare industry; and

•other factors disclosed in the section entitled “Risk Factors” in our Annual Report for the year ended June 30, ~~2022~~2023 filed with the Securities and Exchange Commission (the “SEC”) on September ~~13, 2022, as supplemented by~~12, 2023, and our subsequent filings with the SEC.

We caution you that the important factors referenced above may not contain all of the factors that are important to you. In addition, we cannot assure you that we will realize the results or developments we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our operations in the way we expect. The forward-looking statements included in this Quarterly Report on Form 10-Q are made only as of the date hereof. We undertake no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise, except as otherwise required by law.

Unless otherwise specified or unless the context requires otherwise, all references in this Quarterly Report on Form 10-Q to “InnovAge,” “the Company,” “we,” “us,” and “our,” or similar references, refer to InnovAge Holding Corp. and our consolidated subsidiaries.

PART I —FINANCIAL INFORMATION

Item 1. Financial Statements

INNOVAGE HOLDING CORP. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(In thousands, except per share data)

(Unaudited)

December 31,

June 30,

2022

2022
Assets

Current Assets




Cash and cash equivalents

$
99,460

$
184,429
Short-term investments

45,424

—
Restricted cash

17

17
Accounts receivable, net of allowance ($4,202 – December 31, 2022 and $3,403 – June 30, 2022)

38,643

35,907
Prepaid expenses

12,212

13,842
Income tax receivable

3,733

6,761
Total current assets

199,489

240,956
Noncurrent Assets




Property and equipment, net

185,774

176,260
Operating lease assets

22,223

—
Investments

5,493

5,493
Deposits and other

3,391

2,812
Goodwill

124,217

124,217
Other intangible assets, net

5,528

5,858
Total noncurrent assets

346,626

314,640
Total assets

$
546,115

$
555,596
Liabilities and Stockholders' Equity




Current Liabilities




Accounts payable and accrued expenses

$
48,901

$
50,562
Reported and estimated claims

35,115

38,454
Due to Medicaid and Medicare

11,077

9,130
Current portion of long-term debt

3,794

3,793
Current portion of finance lease obligations

3,864

3,368
Current portion of operating lease obligations

3,434

—
Total current liabilities

106,185

105,307
Noncurrent Liabilities




Deferred tax liability, net

11,379

17,761
Finance lease obligations

9,032

9,440
Operating lease obligations

20,034

—
Other noncurrent liabilities

1,182

1,134
Long-term debt, net of debt issuance costs

66,528

68,210
Total liabilities

214,340

201,852
Commitments and Contingencies (See Note 9)




Redeemable Noncontrolling Interests (See Note 4)

14,054

15,278
Stockholders’ Equity




Common stock, $0.001 par value; 500,000,000 authorized as of December 31, 2022 and June 30, 2022; 135,596,225 and 135,532,811 issued shares as of December 31, 2022 and June 30, 2022, respectively

136

136
Additional paid-in capital

329,777

327,499
Retained earnings (deficit)

(18,137)

4,729
Total InnovAge Holding Corp.

311,776

332,364
Noncontrolling interests

5,945

6,102
Total stockholders’ equity

317,721

338,466
Total liabilities and stockholders’ equity

$
546,115

$
555,596


	December 31, 2023		June 30, 2023
Assets
Current Assets
Cash and cash equivalents	$	54,081	$	127,249
Short-term investments	44,690		46,213
Restricted cash	15		16
Accounts receivable, net of allowance ($5,134 – December 31, 2023 and $4,161 – June 30, 2023)	43,456		24,344
Prepaid expenses	14,460		17,145
Income tax receivable	262		262
Total current assets	156,964		215,229
Noncurrent Assets
Property and equipment, net	195,623		192,188
Operating lease assets	26,477		21,210
Investments	3,611		5,493
Deposits and other	5,154		3,823
Goodwill	141,565		124,217
Other intangible assets, net	4,868		5,198
Total noncurrent assets	377,298		352,129
Total assets	$	534,262	$	567,358
Liabilities and Stockholders' Equity
Current Liabilities
Accounts payable and accrued expenses	$	52,372	$	54,935
Reported and estimated claims	47,247		42,999
Due to Medicaid and Medicare	10,264		9,142
Income tax payable	1,212		1,212
Current portion of long-term debt	3,795		3,795
Current portion of finance lease obligations	4,526		4,722
Current portion of operating lease obligations	3,716		3,530
Deferred revenue	—		28,115
Total current liabilities	123,132		148,450
Noncurrent Liabilities
Deferred tax liability, net	6,555		6,236
Finance lease obligations	11,311		13,114
Operating lease obligations	25,943		18,828
Other noncurrent liabilities	1,187		1,086
Long-term debt, net of debt issuance costs	63,162		64,844
Total liabilities	231,290		252,558
Commitments and Contingencies (See Note 9)
Redeemable Noncontrolling Interests (See Note 4)	11,831		12,708
Stockholders’ Equity
Common stock, $0.001 par value; 500,000,000 authorized as of December 31, 2023 and June 30, 2023; 135,893,070 and 135,639,845 issued shares as of December 31, 2023 and June 30, 2023, respectively	136		136
Additional paid-in capital	335,062		332,107
Retained deficit	(49,695)		(35,944)
Total InnovAge Holding Corp.	285,503		296,299
Noncontrolling interests	5,638		5,793
Total stockholders’ equity	291,141		302,092
Total liabilities and stockholders’ equity	$	534,262	$	567,358

The accompanying notes are an integral part of these condensed consolidated financial statements.

INNOVAGE HOLDING CORP. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(In thousands, except number of shares and per share data)

(Unaudited)

Three Months Ended December 31,

Six Months Ended December 31,

2022

2021

2022

2021
Revenues





Capitation revenue
$
167,140

$
174,964

$
338,071

$
347,518
Other service revenue

316

386

603

902
Total revenues

167,456

175,350

338,674

348,420
Expenses








External provider costs

93,507

91,033

189,744

181,045
Cost of care, excluding depreciation and amortization

51,376

42,911

104,933

83,639
Sales and marketing

3,774

6,679

8,187

12,972
Corporate, general and administrative

28,817

28,482

58,999

49,566
Depreciation and amortization

3,662

3,292

7,095

6,585
Total expenses

181,136

172,397

368,958

333,807
Operating Income (Loss)

(13,680)

2,953

(30,284)

14,613

Other Income (Expense)








Interest expense, net

(223)

(674)

(826)

(1,221)
Other income (expense)

444

28

480

(465)
Total other expense

221

(646)

(346)

(1,686)
Income (Loss) Before Income Taxes

(13,459)

2,307

(30,630)

12,927
Provision (Benefit) for Income Taxes

(2,912)

1,201

(6,383)

4,197
Net Income (Loss)

(10,547)

1,106

(24,247)

8,730
Less: net loss attributable to noncontrolling interests

(754)

(217)

(1,381)

(279)
Net Income (Loss) Attributable to InnovAge Holding Corp.
$
(9,793)

$
1,323

$
(22,866)

$
9,009

Weighted-average number of common shares outstanding - basic

135,578,888

135,516,513

135,572,503

135,516,513
Weighted-average number of common shares outstanding - diluted

135,578,888

135,516,513

135,572,503

135,516,513

Net income (loss) per share - basic
$
(0.07)

$
0.01

$
(0.17)

$
0.07
Net income (loss) per share - diluted
$
(0.07)

$
0.01

$
(0.17)

$
0.07


	Three Months Ended December 31,				Six Months Ended December 31,
	2023		2022		2023		2022
Revenues
Capitation revenue	$	188,561	$	167,140	$	370,734	$	338,071
Other service revenue	337		316		648		603
Total revenues	188,898		167,456		371,382		338,674
Expenses
External provider costs	100,964		93,507		200,322		189,744
Cost of care, excluding depreciation and amortization	54,321		51,376		109,570		104,933
Sales and marketing	5,859		3,774		11,237		8,187
Corporate, general and administrative	25,249		28,817		54,197		58,999
Depreciation and amortization	4,290		3,662		8,559		7,095
Total expenses	190,683		181,136		383,885		368,958
Operating Loss	(1,785)		(13,680)		(12,503)		(30,284)

Other Income (Expense)
Interest expense, net	(935)		(223)		(1,596)		(826)
Other income	874		444		1,517		480
Other expense	(1,882)		—		(1,882)		—
Total other expense	(1,943)		221		(1,961)		(346)
Loss Before Income Taxes	(3,728)		(13,459)		(14,464)		(30,630)
Provision (Benefit) for Income Taxes	93		(2,912)		319		(6,383)
Net Loss	(3,821)		(10,547)		(14,783)		(24,247)
Less: net loss attributable to noncontrolling interests	(374)		(754)		(1,032)		(1,381)
Net Loss Attributable to InnovAge Holding Corp.	$	(3,447)	$	(9,793)	$	(13,751)	$	(22,866)

Weighted-average number of common shares outstanding - basic	135,887,613		135,578,888		135,839,007		135,572,503
Weighted-average number of common shares outstanding - diluted	135,887,613		135,578,888		135,839,007		135,572,503

Net loss per share - basic	$	(0.03)	$	(0.07)	$	(0.10)	$	(0.17)
Net loss per share - diluted	$	(0.03)	$	(0.07)	$	(0.10)	$	(0.17)

The accompanying notes are an integral part of these condensed consolidated financial statements.

INNOVAGE HOLDING CORP. AND SUBSIDIARIES

Condensed Consolidated Statements of Stockholders’ Equity

(In thousands, except share amounts)


	For the Three Months Ended December 31, 2023
	Capital Stock			Additional Paid-in Capital		Retained Earnings (Deficit)		Noncontrolling Interests		Total Permanent Stockholders' Equity		Redeemable Noncontrolling Interests (Temporary Equity)		Net Income (Loss)
	Shares	Amount
Balances, September 30, 2023	135,884,840	$	136	$	333,316	$	(46,248)	$	5,705	$	292,909	12,138
Stock-based compensation	11,552	—		1,766		—		—		1,766		—
Tax withholding related to net share settlements of stock-based compensation awards	(3,322)	—		(20)		—		—		(20)		—
Net loss	—	—		—		(3,447)		(67)		(3,514)		(307)		(3,821)
Balances, December 31, 2023	135,893,070	$	136	$	335,062	$	(49,695)	$	5,638	$	291,141	$	11,831

	For the Six Months Ended December 31, 2023
	Capital Stock			Additional Paid-in Capital		Retained Earnings (Deficit)		Noncontrolling Interests		Total Permanent Stockholders' Equity		Redeemable Noncontrolling Interests (Temporary Equity)		Net Income (Loss)
	Shares	Amount
Balances, June 30, 2023	135,639,845	$	136	$	332,107	$	(35,944)	$	5,793	$	302,092	12,708
Stock-based compensation	359,401	—		3,589		—		—		3,589		—
Tax withholding related to net share settlements of stock-based compensation awards	(106,176)	—		(634)		—		—		(634)		—
Net loss	—	—		—		(13,751)		(155)		(13,906)		(877)		(14,783)
Balances, December 31, 2023	135,893,070	$	136	$	335,062	$	(49,695)	$	5,638	$	291,141	$	11,831

Table of Contents

For the Three Months Ended December 31, 2022

Additional

Retained

Total

Redeemable

Capital Stock

Paid-in

Earnings

Noncontrolling

Permanent

Noncontrolling Interests

Net Income

Shares

Amount

Capital

(Deficit)

Interests

Stockholders' Equity

(Temporary Equity)

(Loss)
Balances, September 30, 2022

135,570,078

$
136

$
328,708

$
(8,344)

$
6,020

$
326,520

14,734

Stock-based compensation

26,147

—

1,069

—

—

1,069

—

Adjustments to redemption value

—

—

—

—

—

—

—

Net loss

—

—

—

(9,793)

(75)

(9,868)

(680)

(10,547)
Balances, December 31, 2022

135,596,225

$
136

$
329,777

$
(18,137)

$
5,945

$
317,721

$
14,054

$

For the Six Months Ended December 31, 2022






Additional

Retained



Total

Redeemable


Capital Stock

Paid-in

Earnings

Noncontrolling

Permanent

Noncontrolling Interests

Net Income

Shares

Amount

Capital

(Deficit)

Interests

Stockholders' Equity

(Temporary Equity)

(Loss)
Balances, June 30, 2022

135,532,811

$
136

$
327,499

$
4,729

$
6,102

$
338,466

15,278

Stock-based compensation

63,414

—

2,278

—

—

2,278

—

Adjustments to redemption value

—

—

—

—

—

—

—

Net loss

—

—

—

(22,866)

(157)

(23,023)

(1,224)

(24,247)
Balances, December 31, 2022

135,596,225

$
136

$
329,777

$
(18,137)

$
5,945

$
317,721

$
14,054

$




	For the Three Months Ended December 31, 2022
	Capital Stock			Additional Paid-in Capital		Retained Earnings (Deficit)		Noncontrolling Interests		Total Permanent Stockholders' Equity		Redeemable Noncontrolling Interests (Temporary Equity)		Net Income (Loss)
	Shares	Amount
Balances, September 30, 2022	135,570,078	$	136	$	328,708	$	(8,344)	$	6,020	$	326,520	14,734
Stock-based compensation	26,147	—		1,069		—		—		1,069		—
Adjustments to redemption value	—	—		—		—		—		—		—
Net loss	—	—		—		(9,793)		(75)		(9,868)		(680)		(10,547)
Balances, December 31, 2022	135,596,225	$	136	$	329,777	$	(18,137)	$	5,945	$	317,721	$	14,054	$

	For the Six Months Ended December 31, 2022
	Capital Stock			Additional Paid-in Capital		Retained Earnings (Deficit)		Noncontrolling Interests		Total Permanent Stockholders' Equity		Redeemable Noncontrolling Interests (Temporary Equity)		Net Income (Loss)
	Shares	Amount
Balances, June 30, 2022	135,532,811	$	136	$	327,499	$	4,729	$	6,102	$	338,466	15,278
Stock-based compensation	63,414	—		2,278		—		—		2,278		—
Adjustments to redemption value	—	—		—		—		—		—		—
Net loss	—	—		—		(22,866)		(157)		(23,023)		(1,224)		(24,247)
Balances, December 31, 2022	135,596,225	$	136	$	329,777	$	(18,137)	$	5,945	$	317,721	$	14,054	$

For the Three Months Ended December 31, 2021

Additional

Retained

Total

Redeemable

Capital Stock

Paid-in

Earnings

Noncontrolling

Permanent

Noncontrolling Interests

Net Income

Shares

Amount

Capital

(Deficit)

Interests

Stockholders' Equity

(Temporary Equity)

(Loss)
Balances, September 30, 2021

135,516,513

$
136

$
324,718

$
18,936

$
6,326

$
350,116

16,431

Stock-based compensation

—

—

783

—

—

783

—

Adjustments to redemption value

—

—

—

(2,564)

—

(2,564)

2,564

Net income (loss)

—

—

—

1,323

(72)

1,251

(145)

1,106
Balances, December 31, 2021

135,516,513

$
136

$
325,501

$
17,695

$
6,254

$
349,586

$
18,850

$

For the Six Months Ended December 31, 2021






Additional

Retained



Total

Redeemable


Capital Stock

Paid-in

Earnings

Noncontrolling

Permanent

Noncontrolling Interests

Net Income

Shares

Amount

Capital

(Deficit)

Interests

Stockholders' Equity

(Temporary Equity)

(Loss)
Balances, June 30, 2021

135,516,513

$
136

$
323,760

$
10,663

$
6,420

$
340,979

16,986

Stock-based compensation

—

—

1,741

—

—

1,741

—

Adjustments to redemption value

—

—

—

(1,977)

—

(1,977)

1,977

Net income (loss)

—

—

—

9,009

(166)

8,843

(113)

8,730
Balances, December 31, 2021

135,516,513

$
136

$
325,501

$
17,695

$
6,254

$
349,586

$
18,850

$

The accompanying notes are an integral part of these condensed consolidated financial statements.

INNOVAGE HOLDING CORP. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited)

For the Six Months Ended December 31,

2022

2021
Operating Activities

Net income (loss)

$
(24,247)

$
8,730
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities




(Gain) loss on disposal of assets

(53)

465
Provision for uncollectible accounts

2,244

2,883
Depreciation and amortization

7,095

6,585
Operating lease rentals

2,335

—
Amortization of deferred financing costs

215

215
Stock-based compensation

2,278

1,741
Deferred income taxes

(6,381)

3,380
Other

(424)

—
Changes in operating assets and liabilities, net of acquisitions




Accounts receivable, net

(4,980)

(3,589)
Prepaid expenses

1,631

(209)
Income tax receivable

3,027

757
Deposits and other

(533)

(89)
Accounts payable and accrued expenses

(544)

7,596
Reported and estimated claims

(3,339)

1,373
Due to Medicaid and Medicare

1,946

1,739
Operating lease liabilities

(2,260)

—
Net cash provided (used) by operating activities

(21,990)

31,577
Investing Activities




Purchases of property and equipment

(14,632)

(11,681)
Purchases of short-term investments

(45,000)

—
Purchase of cost method investment

—

(2,000)
Net cash used in investing activities

$
(59,632)

$
(13,681)
Financing Activities

Payments for finance lease obligations

(1,452)

(1,154)
Principal payments on long-term debt

(1,895)

(1,894)
Net cash used in financing activities

(3,347)

(3,048)

INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS & RESTRICTED CASH

(84,969)

14,848
CASH, CASH EQUIVALENTS & RESTRICTED CASH, BEGINNING OF PERIOD

184,446

203,700
CASH, CASH EQUIVALENTS & RESTRICTED CASH, END OF PERIOD

$
99,477

$
218,548

Supplemental Cash Flows Information




Interest paid

$
1,726

$
984
Income taxes paid

$
13

$
84
Property and equipment included in accounts payable

$
53

$
1,004
Property and equipment purchased under finance leases

$
1,541

$
5,653


	For the Six Months Ended December 31,
	2023		2022
Operating Activities
Net loss	$	(14,783)	$	(24,247)
Adjustments to reconcile net loss to net cash used in operating activities
Gain on disposal of assets	(21)		(53)
Provision for uncollectible accounts	2,881		2,244
Depreciation and amortization	8,559		7,095
Operating lease rentals	2,346		2,335
Amortization of deferred financing costs	215		215
Stock-based compensation	3,589		2,278
Loss on minority equity interest investment	1,882		—
Deferred income taxes	319		(6,381)
Other	9		(424)
Changes in operating assets and liabilities
Accounts receivable, net	(21,430)		(4,980)
Prepaid expenses	3,014		1,631
Income tax receivable	—		3,027
Deposits and other	(1,396)		(533)
Accounts payable and accrued expenses	(2,245)		(544)
Reported and estimated claims	4,137		(3,339)
Due to Medicaid and Medicare	1,122		1,946
Operating lease liabilities	(2,362)		(2,260)
Deferred revenue	(28,115)		—
Net cash used by operating activities	(42,279)		(21,990)
Investing Activities
Purchases of property and equipment	(4,157)		(14,632)
Purchases of short-term investments	(1,179)		(45,000)
Proceeds from sale of short-term investments	3,000		—
Acquisition of business	(23,916)		—
Net cash used in investing activities	$	(26,252)	$	(59,632)
Financing Activities
Payments for finance lease obligations	(2,107)		(1,452)
Principal payments on long-term debt	(1,897)		(1,895)
Taxes paid related to net share settlements of stock-based compensation awards	(634)		—
Net cash used in financing activities	(4,638)		(3,347)

DECREASE IN CASH, CASH EQUIVALENTS & RESTRICTED CASH	(73,169)		(84,969)
CASH, CASH EQUIVALENTS & RESTRICTED CASH, BEGINNING OF PERIOD	127,265		184,446
CASH, CASH EQUIVALENTS & RESTRICTED CASH, END OF PERIOD	$	54,096	$	99,477

Supplemental Cash Flows Information
Interest paid	$	1,254	$	1,726
Income taxes paid	$	—	$	13
Property and equipment included in accounts payable	$	470	$	53
Property and equipment purchased under finance leases	$	113	$	1,541

The accompanying notes are an integral part of these condensed consolidated financial statements.

INNOVAGE HOLDING CORP. AND SUBSIDIARIES

Notes to Condensed Consolidated Financial Statements

Note 1: Business

InnovAge Holding Corp. and its subsidiaries (the "Company") are headquartered in Denver, Colorado. The Company ~~manages, and in many cases directly provides,~~fulfills a broad range of medical and ancillary services for seniors in need of care and support to safely live independently in their ~~homes and~~ communities, including ~~in-home care services (skilled, unskilled and personal care);~~ in-center services such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the Program of All-Inclusive Care for the Elderly (“PACE”) center and third-party medical appointments; and care management. The Company manages its business as one reportable segment, PACE.

As of December 31, ~~2022,~~2023, the Company served approximately ~~6,460~~6,780 PACE participants, making it the largest PACE provider in the United States of America (the “U.S.”) based upon participants served, and ~~operates~~operated 18 PACE centers across California, Colorado, ~~California,~~ New Mexico, Pennsylvania and Virginia.

PACE is a fully-capitated managed care program, which serves the frail elderly, and predominantly dual-eligible, population in a community-based service model. We define dual-eligible seniors as individuals who are 55+ and qualify for benefits under both Medicare and Medicaid. InnovAge ~~is obligated to provide, and participants receive~~provides all needed healthcare services through an all-inclusive, coordinated model of care, and the Company is at risk for 100% of healthcare costs incurred with respect to the care of its participants. PACE programs receive capitation payments directly from Medicare Parts C and D, Medicaid, Veterans ~~Administration~~Affairs (“VA”), and private pay sources. Additionally, under the Medicare Prescription Drug Plan, the Centers for Medicare and Medicaid Services (“CMS”) share part of the risk for providing prescription medication to the Company’s participants.

The Company’s common stock is traded on the Nasdaq Stock Market LLC (“NASDAQ”) under the ticker symbol ~~“INNV.”~~

“INNV”.

Note 2: Summary of Significant Accounting Policies

The Company described its significant accounting policies in Note 2, “Summary of Significant Accounting Policies” of the Notes to Consolidated Financial Statements in its Annual Report on Form 10-K for the year ended June 30, ~~2022~~2023 (“~~2022~~2023 10-K”). With the exception of Recently Adopted Accounting Pronouncements described below, there were no significant changes to those accounting policies during the six months ended December 31, ~~2022.~~

2023.

Basis of Preparation and Principles of Consolidation

The unaudited interim condensed consolidated financial statements and accompanying notes have been prepared in accordance with accounting principles generally accepted in the U.S. (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such regulations. These financial statements have been prepared on a basis consistent with the accounting principles applied for the fiscal year ended June 30, ~~2022.~~2023. In the opinion of management, all adjustments (consisting of all normal and recurring adjustments) considered necessary for a fair presentation have been included. The condensed consolidated financial statements include the accounts of ~~InnovAge,~~the Company, its wholly owned subsidiaries, variable interest entities (“VIEs”)

~~Table of Contents~~

for which it is the primary beneficiary and entities for which it has a controlling interest. All intercompany accounts and transactions have been eliminated in consolidation.

The Company does not have any components of comprehensive income and comprehensive income is equal to net ~~income (loss)~~loss reported in the statements of operations for all periods presented.

Table of Contents

Property and Equipment

Property and equipment were comprised of the following as of December 31, ~~2022~~2023 and June 30, ~~2022:~~

Estimated




dollars in thousands

Useful Lives

December 31, 2022

June 30, 2022
Land

N/A

$
11,980

$
11,980
Buildings and leasehold improvements

10 - 40 years

122,885

122,076
Software

3 - 5 years

27,532

16,264
Equipment and vehicles

3 - 7 years

49,847

47,546
Construction in progress

N/A

37,091

35,479

249,335

233,345
Less: accumulated depreciation and amortization

(63,561)

(57,085)
Total property and equipment, net

$
185,774

$
176,260

2023:


dollars in thousands	Estimated Useful Lives	December 31, 2023		June 30, 2023
Land	N/A	$	11,970	$	11,970
Buildings and leasehold improvements	10 - 40 years	132,553		124,262
Software	3 - 5 years	29,598		26,656
Equipment and vehicles	3 - 7 years	60,687		57,754
Construction in progress	N/A	40,898		42,223
		275,706		262,865
Less: accumulated depreciation and amortization		(80,083)		(70,677)
Total property and equipment, net		$	195,623	$	192,188

Depreciation of ~~$3.3~~$4.1 million and ~~$2.8~~$3.3 million was recorded during the three months ended December 31, ~~2022~~2023 and ~~2021,~~2022, respectively. Depreciation of ~~$6.5~~$8.2 million and ~~$6.1~~$6.5 million was recorded during the six months ended December 31, 2023 and December 31, 2022, ~~and 2021,~~ respectively.

Recently Adopted Accounting Pronouncements

~~Leases~~

Financial Instruments

In ~~February 2016,~~April 2019, the Financial Accounting Standards Board ~~(“FASB”~~("FASB") issued ~~ASU 2016-02~~ ~~Leases~~ (“ASU 2016-02”), which was intended to increase transparency and comparability among organizations by recognizing lease assets and liabilities on the balance sheet and disclosing key information about leasing arrangements. Under the new guidance, lessees are required to recognize a right-of-use (“ROU”Accounting Standards Update ("ASU") asset and a lease liability, measured on a discounted basis, at the commencement date for all leases with terms greater than 12 months. Additionally, this guidance requires enhanced disclosures to help investors and other financial statement users to better understand the amount, timing, and uncertainty of cash flows arising from leases, including qualitative and quantitative requirements. In June 2020, the FASB issued ASU 2020-05 ~~Revenue from contracts with customers (Topic 606) and leases (Topic 842) – Effective dates for certain entities~~ ~~which deferred the new lease standard effective date for the Company to interim periods beginning after December 15, 2021, with early adoption permitted.~~

We adopted the new standard on July 1, 2022 using the modified retrospective transition approach as permitted in ASU 2018-11. In accordance with this approach, the effective date of Topic 842 is also the application date of the new requirements, with prior comparative periods presented in the financial statements with the legacy requirements of ASC Topic 840, Leases. We elected the package of practical expedients which permits us not to reassess under the new lease standard our prior conclusions for lease identification and lease classification on expired or existing contracts and whether initial direct costs previously capitalized would qualify for capitalization under the new lease standard. We also elected to adopt the optional transition method which allows an entity to recognize, if necessary, a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company did not elect the practical expedient to use hindsight in determining the lease term and in assessing impairment conclusions on the ROU assets. Comparative periods presented in the financial statements continue to be presented in accordance with GAAP related to leases prior to transitioning to the new lease standard. The adoption of Topic 842 resulted in the recognition of operating lease liabilities and ROU assets of $25.1 million and $23.6 million, respectively, while our accounting for capital leases (now referred to as finance leases) remained substantially unchanged. The impact of adopting Topic 842 was not material to our Statements of Operations and Statements of Cash Flows. See Note 7, “Leases.”2019-04,

~~Table of Contents~~

~~Recent Accounting Pronouncements Not Yet Adopted~~

~~Financial Instruments~~

~~In April 2019, the FASB issued ASU 2019-04,~~ Codification Improvements to Topic 326, Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments (“ASU 2019-04”), which requires entities to use a current expected credit loss (“CECL”) model to measure impairment for most financial assets that are not recorded at fair value through net income. Under the CECL model, an entity will estimate lifetime expected credit losses considering available relevant information about historical events, current conditions and supportable forecasts. The CECL model does not apply to available-for-sale debt securities. ~~This guidance also expands~~The CECL model is expected to result in more timely recognition of credit losses. The Company adopted the ~~required~~standard on July 1, 2023. Our adoption of the standard did not have a material impact to the condensed consolidated financial statements. The Company makes estimates of expected credit ~~loss~~losses based on a combination of factors, including historical losses adjusted for current market conditions, delinquency trends, aging behaviors of receivables and credit and liquidity indicators, and future market and economic conditions and regularly reviews the adequacy of the allowance for credit losses.

Recent Accounting Pronouncements Not Yet Adopted

Segment Reporting

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures. ASU 2023-07 improves reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses that are regularly provided to the chief operating decision maker. Additionally, ASU 2023-07 requires that all existing annual segment disclosures be provided on an interim basis and clarifies that single reportable segment entities are subject to the disclosure requirement under Topic 280 in its entirety. ASU 2023-07 will be applied ~~using a modified retrospective approach by recording a cumulative effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. ASU 2019-04~~retrospectively and is effective ~~for the Company~~ for fiscal years beginning after December 15, ~~2022, including~~2023 and interim periods ~~within those fiscal years.~~beginning after December 15, 2024. Early adoption is permitted. The Company ~~will adopt this guidance for~~is evaluating the ~~annual and interim reporting periods beginning July 1, 2023. The Company has not determined the effect~~impact of ~~the standard~~ASU 2023-07 on ~~its~~our condensed consolidated financial statements.

Income Taxes

In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures. ASU 2023-09 requires additional disclosures related to rate reconciliation, income taxes paid, and other disclosures. ASU 2023-09 requires public companies to annually (i) disclose specific categories in the rate reconciliation and (ii) provide additional information for reconciling items that meet a quantitative threshold. Additionally, ASU 2023-09 requires public companies to annually disclose the amount of income taxes paid, disaggregated by federal, state, and

Table of Contents

foreign taxes, as well as the amount of income taxes paid by individual jurisdiction. For public companies, ASU 2023-09 is effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact of ASU 2023-09 on our condensed consolidated financial statements.

We do not expect that any other recently issued accounting guidance will have a significant effect on our condensed consolidated financial statements.

Note 3: Revenue Recognition

~~Under ASC 606, revenue~~

Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition, ~~for arrangements that an entity determines are within the scope of ASC 606,~~ the Company performs the following five steps: (i) Identify the contract(s) with a customer; (ii) Identify the performance obligations in the contract; (iii) Determine the transaction price; (iv) Allocate the transaction price to the performance obligations in the contract; and (v) Recognize revenue as the entity satisfies a performance obligation.

Capitation Revenue and Accounts Receivable

Our capitation revenue relates to contracts with participants in which our performance obligation is to provide healthcare services to the participants. Revenues are recorded during the period our obligations to provide healthcare services are satisfied as noted below within each service type. The Company contracts directly with Medicare and Medicaid on a per member, per month (“PMPM”) basis. We receive 100% of the pooled capitated payment to directly provide or manage the healthcare needs of our participants.

Fees are recorded gross in revenues because the Company is acting as a principal in providing for or overseeing comprehensive care provided to the participants. Neither the Company nor any of its affiliates is a registered insurance company because state law in the states in which it operates does not require such registration for risk-bearing providers.

In general, a participant enrolls in the PACE program and is considered a customer of InnovAge. The Company considers all contracts with participants as a single performance obligation to provide comprehensive medical, health, and social services that integrate acute and long-term care. The Company identified that contracts with customers in the PACE program have similar performance obligations and therefore groups them into one portfolio. This performance obligation is satisfied as the Company provides comprehensive care to its participants.

Our revenues are based on the estimated PMPM amounts we expect to be entitled to receive from the capitated fees per participant that are paid monthly by Medicaid, Medicare, the VA, and private pay sources. Medicaid and Medicare capitation revenues are based on PMPM capitation rates under the PACE program. VA is included in “Private Pay and other” and is also capitated. Private pay includes direct payments from participants who do not qualify for the full capitated rate and have to pay all or a portion of the capitated rate. Costs to obtain contracts consist of sales commissions for new enrollees and are included in deposits and ~~other.~~other on our condensed consolidated balance sheets. These costs are amortized over a three-year period which corresponds to

~~Table of Contents~~

the average time a participant is enrolled in the PACE program. As of December 31, ~~2022~~2023 and June 30, ~~2022~~2023, contract assets included within deposits and other were ~~$0.5~~$1.9 million and ~~nil,~~$1.0 million, respectively.

The Company disaggregates capitation revenue from the following sources for the six months ended:

December 31,


2022

2021

Medicaid

55
%
54
%
Medicare

45
%
46
%
Private pay and other

*
%
*
%
Total

100
%
100
%


	December 31,
	2023		2022
Medicaid	55	%	55	%
Medicare	45	%	45	%
Private pay and other	*%		*%
Total	100	%	100	%

* Less than 1%

The Company determined the transaction price for these contracts is the amount we expect to be entitled to, which is the most likely amount. For certain capitation payments, the Company is subject to retroactive premium risk adjustments

Table of Contents

based on various factors. The Company estimates the amount of the adjustment and records it monthly on a straight-line basis. These adjustments are not expected to be material.

The capitation revenues are recognized based on the estimated PMPM transaction price to transfer the service for a distinct increment of the series (i.e. month). We recognize revenue in the month in which participants are entitled to receive comprehensive care benefits during the contract term. As the period between the time of service and time of payment is typically one year or less, the Company elected the practical expedient under ASC 606-10-32-18 and did not adjust for the effects of a significant financing component.

The Company also provides prescription drug benefits in accordance with Medicare Part D. Monthly payments received from CMS and the participants represent the bid amount for providing prescription drug coverage. The portion received from CMS is subject to risk sharing through Medicare Part D risk-sharing corridor provisions. These risk-sharing corridor provisions compare costs targeted in the Company’s bid to actual prescription drug costs. The Company estimates and records a monthly adjustment to Medicare Part D revenues associated with these risk-sharing corridor provisions. Medicare Part D comprised 12% of capitation revenues for each of the three months ended December 31, ~~2022~~2023 and ~~2021.~~2022. Medicare Part D comprised of 12% of capitation revenues for each of the six months ended December 31, ~~2022~~2023 and ~~2021.~~

2022.

Our accounts receivable as of December 31, ~~2022~~2023 and June 30, ~~2022 is~~2023 are primarily from capitation revenue arrangements. The concentration of net receivables from participants and third-party payers was as follows:

December 31,

June 30,

2022

2022

Medicaid

40
%
70
%
Medicare

53
%
22
%
Private pay and other

7
%
8
%
Total

100
%
100
%


	December 31, 2023		June 30, 2023
Medicaid	57	%	61	%
Medicare	36	%	29	%
Private pay and other	7	%	10	%
Total	100	%	100	%

The Company records accounts receivable at net realizable value, which includes an allowance for estimated uncollectible accounts. The allowance for uncollectible accounts reflects the Company’s best estimate of probable losses considering eligibility, historical experience, and existing economic conditions. The balance of the allowance for uncollectible accounts was ~~$4.2~~$5.1 million as of December 31, ~~2022,~~2023, compared to ~~$3.4~~$4.2 million as of June 30, ~~2022.~~2023. Accounts are written off as bad debts when they are deemed uncollectible based upon individual credit evaluations and specific circumstances underlying the accounts.

Other Service Revenue and Accounts Receivable

Other service revenue is comprised of rents earned related to Senior Housing and other fee for service revenue. Other service revenue was 0.2% ~~and 0.2%~~ of total revenue for each of the three months ended December 31, ~~2022~~2023 and ~~2021, respectively.~~

~~Table of Contents~~

2022. Other service revenue was 0.2% ~~and 0.3%~~ of total revenue for each of the six months ended December 31, ~~2022~~2023 and ~~2021, respectively.~~2022. Accounts receivable related to other service revenue was not significant as of both December 31, ~~2022~~2023 and June 30, ~~2022.~~

2023.

Laws and regulations governing the Medicare and Medicaid programs are complex and subject to change, as well as government review. Failure to comply with these laws can expose the entity to significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medicaid programs. See Note 9, “Commitments and Contingencies.”

Note 4: Cost Method and Equity Method Investments

The Company holds ~~equity~~cost method and ~~cost~~equity method investments as of:


in thousands	December 31, 2023		June 30, 2023
Cost method investments	$	2,763	$	4,645
Equity method investments	848		848
Total investments	$	3,611	$	5,493

Table of Contents

December 31,

June 30,
in thousands

2022

2022
Cost method investments

$
4,645

$
4,645
Equity method investments

848

848
Total investments

$
5,493

$
5,493

Nonconsolidated Entities

Cost Method Investments

The Company maintains two investments that are accounted for using the cost method. Our ownership interests are less than 20% of the voting stock of the investments and we do not have the ability to exercise significant influence over the operating and financial policies of the investments. The investments do not have a readily determinable fair value and the Company has elected to record the investments at cost, less impairment, if any, plus or minus any changes resulting from observable price changes in orderly transactions for the identical or similar investment of the same issuer. During the three and six months ended December 31, 2023 we noted indicators of impairment in one of our investments, and recognized impairment loss of $1.9 million, respectively, and is presented as other expense on our condensed consolidated Statements of Operation. During the three and six months ended December 31, 2022, ~~and 2021,~~ there were no observable price changes or impairments recorded.

In August 2021, the Company acquired a minority interest equal to 806,481 shares of the outstanding common

stock of Jetdoc, Inc. (“Jetdoc”), a telehealth and virtual urgent care app dedicated to effectively connecting users with medical professionals, for cash consideration of $2.0 million. Subsequent to December 31, 2023, we noted indicators of impairment in our minority equity investment. We determined that indicators were present as of the reporting date and recognized impairment loss of $1.9 million during the three and six months ended December 31, 2023, which are presented as other expense on our condensed consolidated Statements of Operation. During the three and six months ended December 31, 2022, there were no observable price changes or impairment recorded. The balance of the Company’s investment in Jetdoc as of December 31, 2023 is ~~$2.0~~$0.1 million, which represents the maximum exposure to loss.

On June 14, 2019, the Company invested $1.5 million in DispatchHealth Holdings, Inc. ("DispatchHealth"), through the purchase of a portion of its outstanding Series B Preferred Stock. On April 2, 2020, the Company invested an additional $1.1 million through the purchase of a portion of its outstanding Series C Preferred Stock. The balance of the Company’s investment as of December 31, 2023 is $2.6 million, which represents the maximum exposure to loss.

Equity Method Investments

The Company’s operations include a Senior Housing unit that primarily includes the accounts of Continental Community Housing (“CCH”), the general partner of Pinewood Lodge, LLP (“PWD”), which was organized to develop, construct, own, maintain, and operate certain apartment complexes intended for rental to low-income elderly individuals aged 62 or older.

PWD is a VIE, but the Company is not the primary beneficiary. The Company does not have the power to direct the activities that most significantly impact the economic performance of PWD. Accordingly, the Company does not

~~Table of Contents~~

consolidate PWD. PWD is accounted for using the equity method of accounting. The equity earnings of PWD are insignificant. As of December 31, ~~2022,~~2023, the balance of the Company’s investment in PWD iswas $0.8 million, which represents the maximum exposure to loss.

Noncontrolling Interest

Senior Housing

The Company’s operations include a 0.01% partnership interest in InnovAge Senior Housing Thornton, LLC (“SH1”), which was organized to develop, construct, own, maintain, and operate certain apartment complexes intended for rental to low-income elderly individuals aged 62 or older.

SH1 is a VIE. The Company is the primary beneficiary of SH1 and consolidates SH1. The Company is the primary beneficiary of SH1 as it has the power to direct the activities that are most significant to SH1 and has an obligation to absorb losses or the right to receive benefits from SH1. The most significant activity of SH1 is the operation of the senior

Table of Contents

housing facility. The Company has provided a subordinated loan to SH1 and has provided a guarantee for a convertible term loan held by SH1.

Redeemable Noncontrolling Interest

InnovAge Sacramento

On March 18, 2019, in connection with the formation of InnovAge Sacramento, the joint venture with Adventist Health System/West (“Adventist”) and Eskaton Properties, Incorporated (“Eskaton”), the Company contributed $9.0 million in cash and land valued at $4.2 million for a 59.9% membership interest in the joint ~~venture, InnovAge Sacramento.~~venture. Further, Adventist contributed $5.8 million in cash and Eskaton contributed $3.0 million in cash for membership interests of 26.4% and 13.7%, respectively. In fiscal year 2021, the Company made an additional contribution of $52,000 and obtained an additional 0.1% membership interest in the joint venture, which resulted in the Company obtaining control and consolidating InnovAge Sacramento as of January 1, 2021.

The InnovAge California PACE-Sacramento LLC Limited Liability Company Agreement (the “JV Agreement”) includes numerous provisions whereby, if certain conditions are met, the ~~Joint Venture~~joint venture may be required to purchase, at fair market value, certain members’ interests or certain members may be required to purchase, at fair market value, the interests of certain other members. As of December 31, ~~2022,~~2023, none of the conditions specified in the JV Agreement had been met. At the time the Company became a publicly traded company these put rights held by the noncontrolling interests of the joint venture were required to be presented as temporary ~~equity. The~~equity and are recorded as redeemable noncontrolling interests on our condensed consolidated Balance Sheets. Redeemable noncontrolling interest of ~~$14.1~~$11.8 million ~~was~~and $12.7 million were recorded at carrying value as of December 31, ~~2022.~~

2023 and June 30, 2023, respectively.

Note 5: Fair Value Measurements

Fair value is defined as the price that would be received from selling an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants, at the measurement date. A fair value hierarchy was established that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. Observable inputs are inputs that reflect the assumptions market participants would use in pricing the asset or liability developed based on market data obtained from sources outside the reporting entity. Unobservable inputs are inputs that reflect the Company’s own assumptions based on market data and assumptions that market participants would use in pricing the asset or liability

~~Table of Contents~~

developed based on the best information available in the circumstances. The sensitivity to changes in inputs and their impact on fair value measurements can be significant.

The three levels of inputs that may be used to measure fair value are:

~~Level 1~~

~~Unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access at the measurement date~~

~~Level 2~~

~~Quoted prices in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the assets or liabilities~~

~~Level 3~~

~~Unobservable inputs to the valuation techniques that are significant to the fair value measurements of the assets or liabilities~~

Level 1Unadjusted quoted prices in active markets for identical assets or liabilities that the entity has the ability to access at the measurement date

Level 2Quoted prices in markets that are not active or inputs that are observable, either directly or indirectly, for substantially the full term of the assets or liabilities

Level 3Unobservable inputs to the valuation techniques that are significant to the fair value measurements of the assets or liabilities

Table of Contents

The following table shows the Company’s cash, cash equivalents and marketable securities by significant investment category as of December 31, ~~2022:~~

2022

Cash and

Short-

Amortized

Unrealized

Unrealized

Fair

Cash

term

in thousands

Cost

Gains

Losses

Value

Equivalents

Investments

Cash

$
18,858

$
—

$
—

$
18,858

$
18,858

$
—

Level 1

Money market funds

80,602

—

—

80,602

80,602

—

Mutual funds

45,000

424

—

45,424

—

45,424

Total

$
144,460

$
424

$
—

$
144,884

$
99,460

$
45,424

2023 and June 30, 2023:


	December 31, 2023
in thousands	Amortized Cost		Fair Value		Cash and Cash Equivalents		Short- term Investments
Cash	$	8,038	$	8,038	$	8,038	$	—
Level 1
Money market funds	46,043		46,043		46,043		—
Mutual funds	44,368		44,690		—		44,690
Total	$	98,449	$	98,771	$	54,081	$	44,690

	June 30, 2023
in thousands	Amortized Cost		Fair Value		Cash and Cash Equivalents		Short- term Investments
Cash	$	49,775	$	49,775	$	49,775	$	—
Level 1
Money market funds	77,474		77,474		77,474		—
Mutual funds	46,170		46,213		—		46,213
Total	$	173,419	$	173,462	$	127,249	$	46,213

Recurring Measurements

The Company’s investment in InnovAge Sacramento includes a put right for the noncontrolling interest holders to require the Company to repurchase the interest of the noncontrolling interest holders at fair value, after the initial term of the management services agreement in 2028. As a result, at each fiscal period end the Company reports this put right at the greater of (i) carrying value of the redeemable noncontrolling interest or (ii) fair value of the redeemable noncontrolling interest. Because this asset does not have observable inputs, ~~level~~Level 3 inputs are used to measure fair value. The fair value of the redeemable noncontrolling interest is determined utilizing a discounted cash flow model. As of December 31, ~~2022,~~2023 and June 30, 2023, the Company’s redeemable noncontrolling interest was recorded at carrying value of ~~$14.1 million.~~

$11.8 million and $12.7 million, respectively.

There were no transfers in and out of Level 3 during the six months ended December 31, ~~2022~~2023 or ~~2021.~~

2022.

Note 6: Goodwill and Intangible Assets

Goodwill represents the excess of cost over the fair value of net assets acquired. Goodwill amounted to $141.6 million and $124.2 million at each of December 31, ~~2022~~2023 and June 30, ~~2022.~~2023. Goodwill is not amortized.

Pursuant to ASC 350, “Intangibles – Goodwill and Other,” we review the recoverability of goodwill annually as of April 1 or whenever significant events or changes occur which might impair the recovery of recorded amounts. For purposes of the annual goodwill impairment assessment, the Company has identified ~~three~~two reporting units. There were no indicators of impairment identified and no goodwill impairments recorded during the six months ended December 31, ~~2022~~2023 and ~~2021.~~

Intangible assets consisted of the following as of:

December 31,

June 30,
in thousands

2022

2022
Definite-lived intangible assets

$
6,600

$
6,600
Indefinite-lived intangible assets

2,000

2,000
Total intangible assets

8,600

8,600
Accumulated amortization

(3,072)

(2,742)
Balance as of end of period

$
5,528

$
5,858


in thousands	December 31, 2023		June 30, 2023
Definite-lived intangible assets	$	6,600	$	6,600
Indefinite-lived intangible assets	2,000		2,000
Total intangible assets	8,600		8,600
Accumulated amortization	(3,732)		(3,402)
Balance as of end of period	$	4,868	$	5,198

Intangible assets consist primarily of customer relationships acquired through business acquisitions. The Company recorded amortization expense of $0.2 million ~~and $0.2 million~~ for each of the three months ended December 31, ~~2022~~2023 and ~~2021, respectively.~~2022. The Company recorded amortization expense of $0.3 million ~~and $0.3 million~~ for each of the six months ended December 31, ~~2022~~2023 and ~~2021, respectively.~~

2022.

We review the recoverability of other intangible assets in conjunction with long-lived assets whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable. There were no intangible asset impairments recorded during the six months ended December 31, ~~2022~~2023 and ~~2021.~~

2022

Leasing Arrangements as Lessee

The Company leases certain property and equipment under various third-party operating and finance lease agreements. The Company determines if an arrangement is or contains a lease at the lease inception date by evaluating whether the arrangement conveys the right to use an identified asset and whether the Company obtains substantially all of the economic benefits from and has the ability to direct the use of the asset. The leases are noncancelable and expire on various terms from ~~2023~~2024 through 2032. We determine if an arrangement is a lease upon commencement of the contract. If an arrangement is determined to be a long-term lease (greater than 12 months), we recognize ~~an ROU~~a right-of-use ("ROU") asset and lease liability based on the present value of the future minimum lease payments over the lease term at the commencement date. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at commencement date in determining the present value of future payments. Our lease terms may also include options to extend or terminate the lease when it is reasonably certain that we will exercise those options. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term.

We have elected to apply the short-term lease exception for contracts that have a lease term of twelve months or less and do not include an option to purchase the underlying asset. Therefore, we do not recognize aan ROU asset or lease liability for such contracts. We recognize short-term lease payments as expense on a straight-line basis over the lease term. Variable lease payments that do not depend on an index or rate are recognized as expense. Certain leases include escalations based on inflation indexes and fair market value adjustments. Operating lease liabilities are calculated using the prevailing index or rate at lease commencement for such leases.

The following table presents the components of our ROU assets and their classification in our Balance Sheet at December 31, ~~2022:~~

Component of Lease Balances
Balance Sheet Line Items

Six months ended December 31,

2022

in thousands
Assets:

Operating lease assets
Operating lease assets
$
22,223
Finance lease assets
Property and equipment, net

11,153
Total leased assets

$
33,376
2023:


Component of Lease Balances	Balance Sheet Line Items	December 31, 2023		June 30, 2023
in thousands
Assets:
Operating lease assets	Operating lease assets	$	26,477	$	21,210
Finance lease assets	Property and equipment, net	14,191		16,378
Total leased assets		$	40,668	$	37,588

The following table presents the components of our lease cost and the classification of such costs in our Statements of Operations for the six months ended December ~~31, 2022:~~

Component of Lease Cost
Statements of Operations Line Items

Six months ended December 31,

2022

in thousands
Operating lease cost
Cost of care excluding depreciation and amortization and Corporate, general and administrative
$
2,557
Finance lease expense:

Amortization of leased assets
Depreciation and amortization

1,685
Interest on lease liabilities
Interest expense, net

562
Variable lease cost
Cost of care excluding depreciation and amortization and Corporate, general and administrative

—
Short-term lease cost
Cost of care excluding depreciation and amortization and Corporate, general and administrative

17
Total lease expense

$
4,821

31:


		Six Months Ended December 31,
Component of Lease Cost	Statements of Operations Line Items	2023		2022
in thousands
Operating lease cost	Cost of care excluding depreciation and amortization and Corporate, general and administrative	$	2,382	$	2,557
Finance lease expense:
Amortization of leased assets	Depreciation and amortization	2,301		1,685
Interest on lease liabilities	Interest expense, net	—		562
Variable lease cost	Cost of care excluding depreciation and amortization and Corporate, general and administrative	52		—
Short-term lease cost	Cost of care excluding depreciation and amortization and Corporate, general and administrative	94		17
Total lease expense		$	4,829	$	4,821

The following table includes the weighted-average lease terms and discount rates for operating and finance leases as of December ~~31, 2022:~~

31:

Weighted average remaining lease term:

December 31,

2023

December 31,
2022

Operating leases

14.7 years

~~2022~~

8.8 years

~~Operating leases~~

~~8.8 years~~

Finance leases

3.5 years

3.8 years


Weighted average discount rate:	December 31, 2023		December 31, 2022
Operating leases	12.85	%	6.61	%
Finance leases	7.95	%	8.53	%

~~Weighted average discount rate:~~

~~December 31,~~

~~2022~~

~~Operating leases~~

~~6.61~~

~~Finance leases~~

~~8.53~~

The following table includes the future maturities of lease payments for operating leases and finance leases for periods subsequent to December 31, ~~2022:~~

Operating

Finance

in thousands

Lease

Lease

Total
Amount remaining in 2023

$
2,552

$
2,580

$
5,132
2024

4,542

4,263

8,805
2025

4,136

3,480

7,616
2026

4,061

2,456

6,517
2027

3,764

1,760

5,524
Thereafter

10,302

686

10,988
Total lease payments

29,357

15,225

44,582
Less liability accretion / imputed interest

(5,889)

(2,329)

(8,218)
Total lease liabilities

23,468

12,896

36,364
Less: Current lease liabilities

3,434

3,864

7,298
Total long-term lease liabilities

$
20,034

$
9,032

$
29,066
2023:


in thousands	Operating Lease		Finance Lease		Total
Amount remaining in 2024	$	3,202	$	3,374	$	6,576
2025	5,660		5,325		10,985
2026	5,612		4,302		9,914
2027	5,346		3,576		8,922
2028	4,545		1,767		6,312
Thereafter	13,089		—		13,089
Total lease payments	37,454		18,344		55,798
Less liability accretion / imputed interest	(7,795)		(2,507)		(10,302)
Total lease liabilities	29,659		15,837		45,496
Less: Current lease liabilities	3,716		4,526		8,242
Total long-term lease liabilities	$	25,943	$	11,311	$	37,254

Note

The following table includes the future maturities of minimum rental payments that are required to be paid under all non-cancelable operating and capital lease obligations as previously disclosed in our 2022 Annual Report on Form 10-K as of June 30, 2022, prior to the adoption of ASC 842:

Operating

Capital
in thousands

Lease

Lease
Amount remaining in 2023

$
4,873

$
4,405
2024

4,581

3,909
2025

4,122

3,126
2026

4,061

2,092
2027

3,764

1,393
Thereafter

10,265

535
Total minimal rental payments

31,666

15,460
Less: Amount representing interest

(2,652)
Subtotal

12,808
Current portion

3,368
Long-term portion

$
9,440

~~Note~~8. Long-Term Debt

Long-term debt consisted of the following at December 31, ~~2022~~2023 and June 30, ~~2022:~~

December 31,

June 30,

2022

2022

in thousands
Senior secured borrowings:

Term Loan Facility

$
69,375

$
71,250
Convertible term loan

2,306

2,327
Total debt

71,681

73,577
Less: unamortized debt issuance costs

1,359

1,574
Less: current maturities

3,794

3,793
Noncurrent maturities

$
66,528

$
68,210

2023:

December 31,
2023 June 30,
2023
in thousands
Senior secured borrowings:
Term Loan Facility $ 65,625 $ 67,500
Convertible term loan 2,262 2,284
Total debt 67,887 69,784
Less: unamortized debt issuance costs 930 1,145
Less: current maturities 3,795 3,795
Noncurrent maturities $ 63,162 $ 64,844

2021 Credit Agreement

On March 8, 2021, the Company entered into a credit agreement ~~(the~~(as amended, the “2021 Credit Agreement”) that replaced its prior credit agreement. The 2021 Credit Agreement consists of a senior secured term loan (the “Term Loan Facility”) of $75.0 million principal amount and a revolving credit facility (the “Revolving Credit Facility”) of $100.0 million maximum borrowing capacity, each with a maturity date of March 8, 2026. ~~The remaining~~Borrowing capacity under the Revolving Credit Facility ~~as of December 31, 2022 was $97.2 million,~~is subject to (i) any issued amounts under our letters of credit, which as of December 31, ~~2022~~2023 was ~~$2.8~~$3.1 million, and (ii) applicable to covenant compliance restrictions and any other conditions precedent to borrowing. Loans under the 2021 Credit Agreement are secured by substantially all of the Company’s assets. Principal on the Term Loan Facility is paid each calendar quarter in an amount equal to 1.25% of the initial term loan on closing date. ~~Proceeds of the Term Loan Facility, together with proceeds from the Company’s initial public offering (“IPO”), were used to repay long term debt amounts then outstanding.~~

~~Table of Contents~~

Outstanding principal amounts under the 2021 Credit Agreement accrue interest at a variable interest rate. As of December 31, ~~2022,~~2023, the interest rate on the Term Loan Facility was ~~6.14%~~7.30%. Under the terms of the 2021 Credit Agreement, the Revolving Credit Facility fee accrues at 0.25% of the average daily unused amount and is paid quarterly. As of December 31, ~~2022,~~2023, we had no borrowings outstanding, ~~$2.8~~$3.1 million of letters of credit issued, and ~~$97.2~~$96.9 million of remaining capacity under the Revolving Credit Facility.

The 2021 Credit Agreement requires the Company to meet certain operational and reporting requirements, including, but not limited to, a secured net leverage ratio. Additionally, annual capital expenditures and permitted investments, including acquisitions, are limited to amounts specified in the 2021 Credit Agreement. The 2021 Credit Agreement also provides certain restrictions on dividend payments and other equity transactions and requires the Company to make prepayments under specified circumstances. As of December 31, ~~2022,~~2023, the Company was in compliance with the covenants of the 2021 Credit Agreement.

The deferred financing costs of $2.0 million are amortized over the term of the underlying debt and unamortized amounts have been offset against long-term debt in the condensed consolidated balance sheets. Total amortization of deferred financing costs was $0.1 million for each of the three months ended December 31, 2023 and 2022. Total amortization of deferred financing costs was $0.2 million for each of the six months ended December 31, 2023 and 2022.

Convertible Term Loan

On June 29, 2015, SH1 entered into a convertible term loan. Monthly principal and interest payments of $0.02 million commenced on September 1, 2015. The loan bears interest at an annual rate of 6.68%, with the remaining principal balance due upon maturity at August 20, 2030. The loan is secured by a deed of trust to Public Trustee, assignment of leases and rents, security agreements, and SH1’s fixture filing.

Table of Contents

Note 9: Commitments and Contingencies

Professional Liability

The Company pays fixed premiums for annual professional liability insurance coverage under a claims-made policy. Under such policy, only claims made and reported to the insurer are covered during the policy term, regardless of when the incident giving rise to the claim occurred. The Company records claim liabilities and expected recoveries, if any, at gross amounts. The Company is not currently aware of any unasserted claims or unreported incidents that are expected to exceed medical malpractice insurance coverage limits.

Litigation

From time to time, in the normal course of business, the Company is involved in, or subject to, legal proceedings related to its business, including those described below. The Company regularly evaluates the status of claims and legal proceedings in which it is involved in order to assess whether a loss is probable or there is a reasonable possibility that a loss may have been incurred, and to determine ifwhether accruals are appropriate. The Company expenses legal costs as such costs are incurred.

Civil Investigative Demands

~~Table of Contents~~

On October 14, 2021, and subsequently amended on June 21, 2022, the Company was named as a defendant in a putative class action complaint filed in the District Court for the District of Colorado on behalf of individuals who purchased or acquired shares of the Company’s common stock during a specified period. Through the complaint, plaintiffs are asserting claims against the Company, certain of the Company’s officers and directors, the Company’s former CEO, Apax Partners, L.P., Welsh, Carson, Anderson & Stowe and the underwriters in the Company’s IPO alleging violations of Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 and Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), for making allegedly inaccurate and misleading statements and omissions in connection with the Company’s IPO and subsequent earnings calls and public filings, and seeking to impose control person liability against the officer and director defendants, Apax Partners, L.P. and Welsh, Carson, Anderson & Stowe. The complaint seeks compensatory damages, among other things. On September 13, 2022, the Company and the officer and director defendants and Apax Partners, L.P. and Welsh, Carson, Anderson & Stowe filed a motion to dismiss the amended complaint for failure to state a claim upon which relief can be granted. We are currently unable to predict the outcome of this matter.

In July 2021, the Company received a civil investigative demand from the Attorney General for the State of Colorado under the Colorado Medicaid False Claims Act. The demand requests information and documents regarding Medicaid billing, patient services and referrals in connection with the Company’s PACE program in Colorado. ~~The Company continues~~We continue to fully cooperate with the Attorney General and produce the requested information and documentation. We are currently unable to predict the outcome of this investigation.

In February 2022, the Company received a civil investigative demand from the Department of Justice (“DOJ”) under the Federal False Claims Act on similar subject matter. The demand requests information and documents regarding audits, billing, orders tracking, and quality and timeliness of patient services in connection with the Company’s PACE programs in the states where the Company operates (California, Colorado, New Mexico, Pennsylvania, and Virginia). In December 2022, the Company received a supplemental civil investigative demand requesting supplemental information on the same matters. The Company continues to fully cooperate with the DOJ and produce the requested information and documentation. We are currently unable to predict the outcome of this investigation.

Stockholder Lawsuits

On October 14, 2021, and subsequently amended on June 21, 2022, the Company was named as a defendant in a putative class action complaint filed in the District Court for the District of Colorado on behalf of individuals who purchased or acquired shares of the Company’s common stock during a specified period (the "Securities Action"). Through the complaint, plaintiffs are asserting claims against the Company, certain of the Company’s officers and directors, Apax Partners, L.P., Welsh, Carson, Anderson & Stowe and the underwriters in the Company’s IPO, alleging violations of Sections 11, 12(a)(2) and 15 of the Securities Act of 1933 and Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 for making allegedly inaccurate and misleading statements and omissions in connection with the Company’s IPO and subsequent earnings calls and public filings, and seeking compensatory damages, among other things. On September 13, 2022, the Company and the officer and director defendants and Apax Partners, L.P. and Welsh, Carson, Anderson & Stowe filed a motion to dismiss the amended complaint for failure to state a claim upon which relief can be granted. On December 22, 2023, the District Court granted in part and denied in part the motion to dismiss. The action is now proceeding to discovery.

On April 20, 2022, the Board of Directors of the Company received a books and records demand pursuant to Section 220 of the Delaware General Corporation Law, from a purported stockholder of the Company, Brian Hall, in connection with the stockholder’s investigation of, among other matters, potential breaches of fiduciary duty, mismanagement, self-dealing, corporate waste or other violations of law by the Company’s Board with respect to these matters. On May 15, 2023, Mr. Hall filed a lawsuit in the Delaware Court of Chancery asserting derivative claims for breach of fiduciary duty against certain of the Company’s current and former officers and directors generally relating to alleged failures by the defendants to take remedial actions to address the matters that resulted in sanctions by CMS at certain of the Company’s centers, and alleged misstatements in the Company’s public filings relating to those matters. On June 28, 2023, upon stipulation of the parties, the court entered an order staying the litigation pending the resolution of the motion to dismiss in

Table of Contents

the Securities Action or upon fifteen days’ notice by any party to the litigation. On January 22, 2024, upon stipulation of the parties, the court entered an order further staying the litigation pending the close of fact discovery in the Securities Action.

We are currently unable to predict the outcome of ~~this matter.~~

these matters.

Other Matters

In the third fiscal quarter of 2023, the Company agreed to settle a wage and hour class action lawsuit in the State of California for a cash payment of $1.2 million. Subsequently, the Company was notified of certain additional individual claims and has agreed to include such claims within the class. As a result, in October 2023, the Company agreed to increase the settlement amount to a total of $1.3 million. The agreement is subject to court approval, which we expect to occur in the second half of fiscal 2024.

Because the results of legal proceedings and claims are inherently unpredictable and uncertain, we are currently unable to predict whether the legal proceedings we are involved in will, either individually or in the aggregate, have a material adverse effect on our business, financial condition, or cash flows. The outcomes of legal proceedings and claims could be material to the Company’s operating results for any particular period, depending in part, upon the operating results of such period. Regardless of the outcome, litigation has the potential to have an adverse impact on us due to any related defense and settlement costs, diversion of management resources, and other factors.

~~Table of Contents~~

Note 10: Stock-based Compensation

A summary of our aggregate stock-based compensation expense is set forth below. Stock-based compensation expense is included in corporate, general and administrative expenses on our condensed consolidated ~~statements~~Statements of ~~operations.~~

Six months ended December 31,

Three months ended December 31,

2022

2021

2022

2021

in thousands

in thousands

Stock options
$
533

$
90

$
261

$
90
Profits interests units

456

1,029

202

439
Restricted stock units

1,523

622

749

254
Total stock-based compensation expense
$
2,512

$
1,741

$
1,212

$
783

Operations.

Three months ended December 31, Six months ended December 31,
2023 2022 2023 2022
in thousands in thousands
Stock options $ 216 $ 261 $ 439 $ 533
Profits interests units 253 202 629 456
Restricted stock units 1,297 749 2,521 1,523
Total stock-based compensation expense $ 1,766 $ 1,212 $ 3,589 $ 2,512

2020 Equity Incentive Plan

Profits Interests

TCO Group Holdings, L.P. (the “LP”), the Company’s largest shareholder and prior to the IPO, the Company’s parent, maintains the ~~2020~~TCO Group Holdings, L.P. Equity Incentive Plan (the "2020 Equity Incentive Plan") pursuant to which interests in the LP in the form of Class B Units (profits interests) ~~could~~can be granted to employees, directors, consultants, advisers, and ~~advisers.~~other service providers (including partners) of the LP or any of its affiliates, including the Company. A maximum number of 16,162,177 Class B Units ~~were~~are authorized for grant under the 2020 Equity Incentive ~~Plan.~~Plan, and both performance-based and time-based units have been issued under the plan. As of December 31, ~~2022,~~2023, a total of ~~13,009,137~~15,222,837 profits interests units had been granted under the 2020 Equity Incentive Plan.

The Company used the Monte Carlo option model to determine the fair value of the profits interests units at the time of the grant. ~~There~~A total of 2,213,700 Class B Units were ~~no grants following the IPO and~~awarded during the six months ended December 31, ~~2022.~~

2023 to the Company's Chief Executive Officer, Chief Financial Officer, and Chief Legal Officer. The assumptions under the Monte Carlo model related to the profits interests units, presented on a weighted-average basis, are provided below:

Table of Contents


		2023
Expected volatility		74.0-76.0	%
Expected life (years) - time vesting units		3.0 - 3.1
Interest rate		4.52 - 4.57	%
Dividend yield		—
Weighted-average fair value	$	1.95 - 2.17
Fair value of underlying stock	$	5.53 - 7.27

A summary of profits interests activity for the six months ended December 31, ~~2022 was~~2023 is as follows:

Number of

Weighted average
Time-based unit awards

units

grant date fair value

Outstanding balance, June 30, 2022

2,158,072

$
1.28
Granted

—

$
—
Forfeited

(49,654)

$
1.28
Vested

(844,081)

$
1.28
Outstanding balance, December 31, 2022

1,264,337

$
1.28

Number of

Weighted average
Performance-based unit awards

units

grant date fair value

Outstanding balance, June 30, 2022

2,217,865

$
0.57
Granted

—

$
—
Forfeited

(99,307)

$
0.57
Vested

—

$
—
Outstanding balance, December 31, 2022

2,118,558

$
0.57


Time-based unit awards	Number of units	Weighted average grant date fair value

Outstanding balance, June 30, 2023	1,264,337	$	1.28
Granted	1,106,850	$	6.21
Forfeited	(380,679)	$	1.28
Vested	(703,395)	$	1.28
Outstanding balance, December 31, 2023	1,287,113	$	5.52


Performance-based unit awards	Number of units	Weighted average grant date fair value

Outstanding balance, June 30, 2023	2,118,558	$	0.57
Granted	1,106,850	$	1.85
Forfeited	(1,853,737)	$	0.57
Vested	—	$	—
Outstanding balance, December 31, 2023	1,371,671	$	1.60

The total unrecognized compensation cost related to profits interests units outstanding as of December 31, ~~2022~~2023 was ~~$2.5~~$4.0 million, comprised (i) ~~$1.3~~$1.8 million related to time-based unit awards expected to be recognized over a weighted-average period of ~~0.9~~2.9 years and (ii) ~~$1.2~~$2.2 million related to performance-based unit awards, which will be recorded when it is probable that the performance-based criteria will be met.

~~Table of Contents~~

2021 Omnibus Incentive Plan

In March 2021, the compensation committee of our Board of Directors approved the InnovAge Holding Corp. 2021 Omnibus Incentive Plan (the “2021 Omnibus Incentive Plan”), pursuant to which various stock-based awards may be granted to employees, directors, consultants, and advisers. The total number of shares of the Company’s common stock authorized under the 2021 Omnibus Incentive Plan is 14,700,000. The Company has issued time-based restricted stock units under this plan to its employees which generally vest (i) on March 4, 2023, the second anniversary of the grant date, or (ii) over a three-year period with ~~one-third~~one-third vesting on each anniversary of the date of grant. Certain other vesting periods have also been used. The grant date fair value of restricted stock units with time based vesting is based on the closing market price of our common stock on the date of grant. Certain awards under this plan vest upon achieving specific share price performance criteria and are determined to have performance-based vesting conditions. The Company has also issued time-based stock options under this plan to its employees which generally vest at various intervals over a three-year period. ~~Certain awards under this plan vest upon achieving specific share price performance criteria and are determined to have performance-based vesting conditions.~~

Table of Contents

Restricted Stock Units

A summary of time-based vesting restricted stock units activity for the six months ended December 31, ~~2022 was~~2023 is as follows:

Weighted

average

Number of

grant-date fair
Restricted stock units - time based

awards

value per share

Outstanding balance, June 30, 2022

476,768

$
9.69
Granted

986,200

$
5.97
Forfeited

(155,741)

$
5.48
Vested

(97,727)

$
4.50
Outstanding balance, December 31, 2022

1,209,500

$
6.41


Restricted stock units - time based	Number of awards	Weighted average grant-date fair value per share

Outstanding balance, June 30, 2023	1,873,794	$	10.10
Granted	437,248	$	5.53
Forfeited	(23,493)	$	4.56
Vested	(329,707)	$	5.88
Outstanding balance, December 31, 2023	1,957,842	$	9.86

The total unrecognized compensation cost related to time based restricted stock units outstanding as of December 31, ~~2022~~2023 was ~~$5.1~~$7.6 million and is expected to be recognized over a weighted-average period of ~~2.3~~1.9 years.

A summary of performance based vesting restricted stock units activity for the six months ended December 31, ~~2022 was~~2023 is as follows:

Weighted

average

Number of

grant-date fair
Restricted stock units - performance based

awards

value per share

Outstanding balance, June 30, 2022

258,767

$
5.18
Granted

—

$
—
Forfeited

—

$
—
Vested

—

$
—
Outstanding balance, December 31, 2022

258,767

$
5.18


Restricted stock units - performance based	Number of awards	Weighted average grant-date fair value per share

Outstanding balance, June 30, 2023	258,767	$	5.18
Granted	—	$	—
Forfeited	—	$	—
Vested	—	$	—
Outstanding balance, December 31, 2023	258,767	$	5.18

The total unrecognized compensation cost related to performance based vesting restricted stock units outstanding as of December 31, ~~2022~~2023 was ~~$1.0~~$0.6 million and is expected to be recognized over a weighted-average period of ~~2.8~~1.9 years.

~~Table of Contents~~

Nonqualified Stock Options

A summary of time-based vesting stock option activity for the six months ended December 31, ~~2022 was~~2023 is as follows:


Stock options - time based	Number of awards	Weighted average grant-date fair value per share

Outstanding balance, June 30, 2023	716,661	$	1.43
Granted	—	$	—
Forfeited	—	$	—
Exercised	—	$	—
Expired	—	$	—
Outstanding balance, December 31, 2023	716,661	$	1.43

Exercisable balance, December 31, 2023	330,761	$	0.18

Table of Contents

Weighted

average

Number of

grant-date fair
Stock options - time based

awards

value per share

Outstanding balance, June 30, 2022

554,499

$
1.61
Granted

81,082

$
0.80
Forfeited

—

$
—
Vested

(138,624)

$
0.28
Outstanding balance, December 31, 2022

496,957

$
0.90

The total unrecognized compensation cost related to time-based vesting stock options outstanding as of December 31, ~~2022~~2023 was ~~$0.5~~$0.2 million and is expected to be recognized over a weighted-average period of ~~2.4~~1.8 years.

The fair value of the time-based stock options granted during the six months ended December 31, 2022, was based upon the Black-Scholes option pricing model using the assumptions in the following table:

2022

Expected volatility

34.5
%
Weighted-average expected life (years) - time vesting units

2.9

Interest rate

1.56
%
Dividend yield

0
%
Weighted-average fair values

$
0.80

Fair value of underlying stock

$
3.70

A summary of performance-based vesting stock option activity for the six months ended December 31, ~~2022 was~~2023 is as follows:

Weighted

average

Number of

grant-date fair
Stock options - performance based

awards

value per share

Outstanding balance, June 30, 2022

776,299

$
3.08
Granted

—

$
—
Forfeited

—

$
—
Vested

—

$
—
Outstanding balance, December 31, 2022

776,299

$
3.08


Stock options - performance based	Number of awards	Weighted average grant-date fair value per share

Outstanding balance, June 30, 2023	776,299	$	3.08
Granted	—	$	—
Forfeited	—	$	—
Vested	—	$	—
Outstanding balance, December 31, 2023	776,299	$	3.08

The total unrecognized compensation cost related to performance-based vesting stock options outstanding as of December 31, ~~2022~~2023 was ~~$1.7~~$1.1 million and is expected to be recognized over a weighted-average period of ~~2.9~~2.0 years.

Note 11: Acquisitions

On December 1, 2023, the Company acquired all of the issued and outstanding membership interests of two California-based PACE programs, ConcertoCare PACE of Bakersfield, LLC and ConcertoHealth PACE of Los Angeles, LLC (collectively "Concerto"), from Perfect Health, Inc. d/b/a ConcertoCare, a tech-enabled, value-based provider of at-home, comprehensive care for seniors and other adults with unmet health and social needs, for $23.9 million. We believe the Concerto acquisition compliments our California PACE centers. The acquisition was funded through cash on hand. Results of operations from the acquisition are included in our condensed consolidated Statements of Operations for the three and six months ended December 31, 2023 and were not significant to our results. We incurred costs related to the acquisition of approximately $0.1 million during the six months ended December 31, 2023. Acquisition related costs were expensed as incurred and have been recorded in corporate, general and administrative expenses in our condensed consolidated Statements of Operations.

The Concerto acquisition was accounted for using the purchase method of accounting. The purchase price has been preliminarily allocated to the assets acquired and liabilities assumed based on their estimated fair values at the date of acquisition. The fair values of assets acquired and liabilities assumed may change as the valuation of intangible assets and overall purchase price allocation is being finalized. Goodwill represents the excess of the purchase price over the fair value

Table of Contents

of net assets acquired. Goodwill recognized represents the estimated future economic benefits arising from expected growth opportunities for the Company and is not deductible for income tax purposes.

The following table presents a preliminary allocation of the purchase price to the assets acquired and liabilities assumed as of the acquisition date:


	December 1, 2023
	in thousands
Cash Consideration	$	23,916
Total Consideration	$	23,916

Accounts receivable, net	$	563
Prepaid expenses	330
Property and equipment, net	7,969
Operating lease assets	6,892
Goodwill	17,348
Deposits and other	343
Accounts payable and accrued expenses	(353)
Reported and estimated claims	(111)
Operating lease obligations	(8,941)
Finance lease obligations	(124)
Fair value of assets and liabilities	$	23,916

Note 12: Income Taxes

The Company recorded an income tax ~~benefit~~expense of ~~$2.9~~$0.1 million and an income tax ~~provision~~benefit of ~~$1.2~~$2.9 million for the three months ended December 31, ~~2022~~2023 and ~~2021,~~2022, respectively. The Company recorded an income tax ~~benefit~~expense of ~~$6.4~~$0.3 million and an income tax ~~provision~~benefit of ~~$4.2~~$6.4 million for the six months ended December 31, ~~2022~~2023 and ~~2021, respectively. This~~

~~Table of Contents~~

~~represents an effective tax rate of 20.9% and 32.5% for the three months ended December 31,~~ 2022, ~~and 2021,~~ respectively. This represents an effective tax rate of (2.5)% and 20.9% for the three months ended December 31, 2023 and ~~32.5%~~2022, respectively. This represents an effective tax rate of (2.2)% and 20.9% for the six months ended December 31, 2023 and 2022, ~~and 2021,~~ respectively.

The effective rate for the six months ended December 31, ~~2022~~2023 was different from the federal statutory rate primarily due to the Company’s book loss offset partially by disallowed officers’ compensation under Internal Revenue Code (“IRC”) Section 162(m), disallowed stock options related to the profit interest units, exclusion of losses from entities not subject to tax, ~~and~~ lobbying expenses, and the increase in the Company's valuation allowance against Net operating losses which occurred during the ~~three month~~three-month period.

The Company assesses the valuation allowance recorded against deferred tax assets at each reporting date. The determination of whether a valuation allowance for deferred tax assets is appropriate requires the evaluation of positive and negative evidence that can be objectively verified. Consideration must be given to all sources of taxable income available to realize deferred tax assets, including, as applicable, the future reversal of existing temporary differences, future taxable income forecasts exclusive of the reversal of temporary differences and carryforwards, taxable income in carryback years and tax planning strategies. In estimating income taxes, the Company assesses the relative merits and risks of the appropriate income tax treatment of transactions taking into account statutory, judicial, and regulatory guidance. As of the six-month period ended December 31, ~~2022,~~2023, the Company ~~has~~ determined that it is not “more likely than not” that the deferred tax assets associated with certain state net operating losses will be realized and as such continues to maintain a valuation allowance against these state deferred tax assets. The Company also determined it is not "more likely than not" that the deferred tax assets associated with certain federal net operating losses will be realized and as such has included a valuation allowance against these federal deferred tax assets. The Company has provided ~~$4.1~~$16.8 million at ~~each of~~ December 31, ~~2022~~2023 and $8.3 million at June 30, ~~2022,~~2023, as a valuation allowance against its deferred tax assets for federal and state net operating losses where there is not sufficient positive evidence to substantiate that these deferred tax assets will be realized at a more-likely-than-not level of assurance.

Table of Contents

Note ~~12:~~13: Earnings per Share

Basic earnings (loss) per share (“EPS”) is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted-average number of common shares outstanding during the period, plus the dilutive effect of outstanding options, using the treasury stock method and the average market price of the Company’s common stock during the applicable period. When a loss from continuing operations exists, all dilutive securities and potentially dilutive securities are anti-dilutive and are therefore excluded from the computation of diluted ~~earnings per share.~~EPS. When net income from continuing operations exists, performance-based units, are omitted from the calculation of diluted EPS until it is determined that the performance criteria has been met at the end of the reporting period. For the three and six months ended December 31, ~~2022, 424,316~~2023, 391,598 and ~~14,076~~377,025 potentially diluted securities ~~respectively,~~ were excluded from the weighted-average shares used to calculate the diluted net loss per common share, respectively, as they would have an anti-dilutive effect. ~~There were no potentially dilutive shares for~~During the three and six months ended December 31, ~~2021, therefore, there was no difference between basic~~2022, 424,316 and 14,076 potentially dilutive securities were excluded from the weighted average shares used to calculate the diluted net loss per common ~~shares.~~

share, respectively, as they would have an anti-dilutive effect.

~~Table of Contents~~

The following table sets forth the computation of basic and diluted net loss per common share:

Three months ended December 31,

Six months ended December 31,
in thousands, except share values

2022

2021

2022

2021
Net income (loss) attributable to InnovAge Holding Corp.

$
(9,793)

$
1,323

$
(22,866)

$
9,009
Weighted average common shares outstanding (basic)

135,578,888

135,516,513

135,572,503

135,516,513
EPS (basic)

$
(0.07)

$
0.01

$
(0.17)

$
0.07

Dilutive shares

—

—

—

—
Weighted average common shares outstanding (diluted)

135,578,888

135,516,513

135,572,503

135,516,513
EPS (diluted)

$
(0.07)

$
0.01

$
(0.17)

$
0.07


	Three months ended December 31,				Six months ended December 31,
in thousands, except share values	2023		2022		2023		2022
Net loss attributable to InnovAge Holding Corp.	$	(3,447)	$	(9,793)	$	(13,751)	$	(22,866)
Weighted average common shares outstanding (basic)	135,887,613		135,578,888		135,839,007		135,572,503
EPS (basic)	$	(0.03)	$	(0.07)	$	(0.10)	$	(0.17)

Dilutive shares	—		—		—		—
Weighted average common shares outstanding (diluted)	135,887,613		135,578,888		135,839,007		135,572,503
EPS (diluted)	$	(0.03)	$	(0.07)	$	(0.10)	$	(0.17)

Note ~~13:~~14: Segment Reporting

The Company applies ASC Topic 280, "Segment Reporting," which establishes requirements to report selected segment information quarterly and to report annually entity-wide disclosures about operations, major customers and the geographies in which the entity holds material assets and reports revenue. An operating segment is defined as a component that engages in business activities whose operating results are reviewed by the Company’s chief executive officer, who is the chief operating decision maker (“CODM”), and for which discrete financial information is available. The Company has determined that it has ~~five~~three operating segments, ~~three~~two of which are related to the Company’s PACE offering. The PACE-related operating segments are based on ~~three~~two geographic divisions, which are ~~West, Central,~~East and ~~East.~~West. Due to the similar economic characteristics, nature of services, and customers, we have aggregated our ~~West, Central,~~East and ~~East~~West operating segments into one reportable segment for PACE. The Company’s remaining ~~two~~ operating ~~segments relate~~segment primarily relates to ~~Homecare and~~ Senior Housing, which ~~are~~is an immaterial operating ~~segments,~~segment, and ~~are~~ shown below as "Other" along with certain corporate unallocated expenses.

The Company evaluates performance and allocates capital resources to each segment based on an operating model that is designed to maximize the ~~provision~~quality of ~~services~~care provided and profitability. The Company does not review assets by segment and therefore assets by segment are not disclosed below. For the periods presented, all of the Company’s long-lived assets were located in the United States and all revenue was earned in the United States.

The Company’s management uses Center-level Contribution Margin as the measure for assessing performance of its operating segments. Center-level Contribution Margin is defined as total segment revenues less external provider costs and cost of care (excluding depreciation and amortization)~~, which includes all medical and pharmacy costs.~~. The Company allocates corporate level expenses to its segments with a majority of the allocation going to the PACE segment.

Table of Contents

The following table summarizes the operating results regularly provided to the CODM by reportable segment for the three months ended December 31, ~~2022~~2023 and ~~2021:~~

December 31, 2022

December 31, 2021
(In thousands)

PACE

All other⁽¹⁾

Totals

PACE

All other⁽¹⁾

Totals
Capitation revenue

$
167,140

$
—

$
167,140

$
174,964

$
—

$
174,964
Other service revenue

99

217

316

60

326

386
Total revenues

167,239

217

167,456

175,024

326

175,350
External provider costs

93,507

—

93,507

91,033

—

91,033
Cost of care, excluding depreciation and amortization

51,184

192

51,376

42,478

433

42,911
Center-Level Contribution Margin

22,548

25

22,573

41,513

(107)

41,406
Overhead costs⁽²⁾

32,532

59

32,591

35,160

1

35,161
Depreciation and amortization

3,555

107

3,662

3,185

107

3,292
Interest expense, net

(177)

(46)

(223)

(624)

(50)

(674)
Other expense (income)

444

—

444

29

(1)

28
Income (Loss) Before Income Taxes

$
(13,272)

$
(187)

$
(13,459)

$
2,573

$
(266)

$
2,307

2022:


	December 31, 2023						December 31, 2022
(In thousands)	PACE		All other(1)		Totals		PACE		All other(1)		Totals
Capitation revenue	$	188,561	$	—	$	188,561	$	167,140	$	—	$	167,140
Other service revenue	68		269		337		99		217		316
Total revenues	188,629		269		188,898		167,239		217		167,456
External provider costs	100,964		—		100,964		93,507		—		93,507
Cost of care, excluding depreciation and amortization	54,171		150		54,321		51,184		192		51,376
Center-Level Contribution Margin	33,494		119		33,613		22,548		25		22,573
Overhead costs(2)	31,108		—		31,108		32,532		59		32,591
Depreciation and amortization	4,178		112		4,290		3,555		107		3,662
Interest expense, net	890		45		935		177		46		223
Other income	(874)		—		(874)		(444)		—		(444)
Other expense	1,882		—		1,882		—		—		—
Loss Before Income Taxes	$	(3,690)	$	(38)	$	(3,728)	$	(13,272)	$	(187)	$	(13,459)

The following table summarizes the operating results regularly provided to the CODM by reportable segment for the six months ended December 31, ~~2022~~2023 and ~~2021:~~2022:


	December 31, 2023						December 31, 2022
in thousands	PACE		All other(1)		Totals		PACE		All other(1)		Totals
Capitation revenue	$	370,734	$	—	$	370,734	$	338,071	$	—	$	338,071
Other service revenue	153		495		648		176		427		603
Total revenues	370,887		495		371,382		338,247		427		338,674
External provider costs	200,322		—		200,322		189,744		—		189,744
Cost of care, excluding depreciation and amortization	109,267		303		109,570		104,595		338		104,933
Center-Level Contribution Margin	61,298		192		61,490		43,908		89		43,997
Overhead costs(2)	65,425		9		65,434		67,107		79		67,186
Depreciation and amortization	8,334		225		8,559		6,881		214		7,095
Interest expense, net	1,506		90		1,596		735		91		826
Other income	(1,517)		—		(1,517)		(480)		—		(480)
Other expense	1,882		—		1,882		—		—		—
Income (Loss) Before Income Taxes	$	(14,332)	$	(132)	$	(14,464)	$	(30,335)	$	(295)	$	(30,630)

December 31, 2022

December 31, 2021
in thousands

PACE

All other⁽¹⁾

Totals

PACE

All other⁽¹⁾

Totals
Capitation revenue

$
338,071

$
—

$
338,071

$
347,518

$
—

$
347,518
Other service revenue

176

427

603

69

833

902
Total revenues

338,247

427

338,674

347,587

833

348,420
External provider costs

189,744

—

189,744

181,045

—

181,045
Cost of care, excluding depreciation and amortization

104,595

338

104,933

82,579

1,060

83,639
Center-Level Contribution Margin

43,908

89

43,997

83,963

(227)

83,736
Overhead costs⁽²⁾

67,107

79

67,186

62,551

(13)

62,538
Depreciation and amortization

6,881

214

7,095

6,370

215

6,585
Interest expense, net

(735)

(91)

(826)

(1,120)

(101)

(1,221)
Other expense (income)

480

—

480

(464)

(1)

(465)
Income (Loss) Before Income Taxes

$
(30,335)

$
(295)

$
(30,630)

$
13,458

$
(531)

$
12,927

(1)Center-level Contribution Margin from segments below the quantitative thresholds are primarily attributable to ~~two~~the Senior Housing operating ~~segments~~segment of the Company. ~~Those segments consist of Homecare and Senior Housing. Neither of those segments~~This segment has ~~ever~~never met any of the quantitative thresholds for determining reportable segments.

~~(2)~~

~~Overhead consists of the Sales and marketing and Corporate, general and administrative financial statement line items.~~

(2)

Overhead consists of the Sales and marketing and Corporate, general and administrative financial statement line items.

Note ~~14:~~15: Related Party Transactions

Pursuant to the PWD Amended and Restated Agreement of Limited Partnership, the general partner, ~~who~~which is a subsidiary of the Company (the “General Partner”), ~~helped fund~~funds operating deficits and shortfalls of PWD in the form of a loan. At each of December 31, ~~2022~~2023 and June 30, ~~2022,~~2023, $0.7 million was recorded in Deposits and other. Additionally, the General Partner is paid an administration fee of $35,000 per year.

Table of Contents

Note ~~15:~~16: Subsequent Events

~~On January 23, 2023, CMS and~~

The Company has evaluated subsequent events through the ~~Colorado Department of Healthcare Policy & Financing (“HCPF”) released~~date on which the enrollment sanctions for all of our Colorado centers. CMS and HCPF will require the Company to conduct post-sanction corrective action and monitoring activities to address any issues identified during the validation audits. The release of both sanctions permits the Company to resume normal enrollment of eligible Colorado seniors into its PACE program at its six Colorado centers.

condensed consolidated financial statements were issued.

Table of Contents

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our condensed consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q. The discussion contains forward-looking statements that are based on the beliefs of management, as well as assumptions made by, and information currently available to our management. Readers are cautioned not to place undue reliance on any forward-looking statements, as forward-looking statements are not guarantees of future performance and the Company’s actual results may differ significantly due to numerous known and unknown risks and uncertainties, including those discussed below and in the section entitled “Cautionary Note on Forward-Looking Statements.” Those known risks and uncertainties include, but are not limited to, the risk factors identified in the section titled “Risk Factors” in this Quarterly Report on Form 10-Q and in our Annual Report on Form 10-K for the fiscal year ended June 30, ~~2022~~2023 (“~~2022~~2023 10-K”).

Overview

InnovAge Holding Corp. (“InnovAge”) became a public company in March 2021. As of December 31, ~~2022,~~2023, the Company served approximately ~~6,460~~6,780 PACE participants, and operated 18 PACE centers across California, Colorado, ~~California,~~ New Mexico, Pennsylvania, and Virginia.

Trends and Uncertainties Affecting the Company

Macroeconomic conditions. During fiscal year ~~2022,~~2024, the U.S. ~~and global economies experienced adverse macroeconomic effects in part resulting from the ongoing effects of the COVID-19 pandemic, as discussed in more detail below. These effects included~~continued to wrestle with inflation and increased wages due to labor ~~shortages.~~shortages and increased competition among healthcare professionals. In fiscal year 2022 and 2023, in response to high levels of inflation, we ~~began to implement~~implemented various mitigation strategies to reduce costs of operation, including, consolidating services, ~~and~~ price negotiations with providers and ~~vendors. While inflationary pressures eased slightly during the three~~vendors and ~~six months ended~~limiting corporate staffing, effecting a reduction in workforce in December ~~31,~~2022. For example, in fiscal year 2023, we launched and conducted several initiatives intended to lower certain of our costs, including limiting corporate staffing, effecting a reduction in workforce in December 2022, ~~inflation has continued during the first half of fiscal 2023~~ and ~~is expected to continue through the remainder of the fiscal year. As a result, the~~optimizing working capital. The Company has continued ~~the~~these mitigation strategies ~~discussed~~ during the six months ended December 31, ~~2022.~~2023. For example, in October 2023, we conducted an additional planned reduction in workforce involving approximately 1.6% of our workforce. In connection with the planned reduction, we incurred approximately $0.3 million of charges associated with employee severance and benefits costs during the three months ended December 31, 2023. The effects of inflation, after accounting for these mitigation strategies, were immaterial to our financial results for the three and six months ended December 31, ~~2022.~~2023. We expect to continue to experience elevated operating expenses for the remainder of fiscal 2024 for similar reasons. Although we expect to continue mitigation efforts, there can be no assurance that our strategies will be sufficient.

~~In addition, the increased wage pressure, exacerbated by the labor shortage, increased the~~

Increased cost of ~~providing~~care. Cost of care and ~~our overall operating expenses during the six months ended December 31, 2022. The combination of~~related cost per participant increased wage pressure and labor shortage amongst healthcare personnel, and specifically, trained personnel, has impacted and may continue to impact our expenses and ability to adhere to the complex government laws and regulations that apply to our business.

~~Furthermore, operating expenses increased $35.2 million, or 10.5%,~~ for the six months ended December 31, ~~2022~~2023 compared to ~~2021 due to, in part, the increased cost of care and related cost per participant~~2022, partially as a result of increased salaries, wages and benefits associated with increased headcount and higher wage rates ~~third party audit~~ and ~~compliance support,~~ increased fleet and contract transportation costs due to an increase in center attendance and external appointments as well as increased costs related to growing census. Additionally, external provider costs have increased in the six month period ended December 31, 2023 compared to 2022 associated with annual increases in assisted living and ~~higher fuel costs.~~nursing facility unit cost and general medical inflation. We ~~expect to experience elevated operating expenses for the remainder of fiscal 2023. We~~will continue to evaluate increased costs and methods to mitigate or offset such ~~costs.~~

~~Impact of Macroeconomic Conditions~~increases.

Census and ~~COVID-19~~

~~The~~capitation revenue. On May 11, 2023 the President allowed the national emergency and public health emergency declarations related to the COVID-19 pandemic ~~altered~~to expire. While states have resumed processing new Medicaid applications and redeterminations of beneficiary eligibility, the ~~behavior~~healthcare industry has experienced increased delays in the processing of ~~businesses~~such applications. The Company completes annual Medicaid redeterminations, which enables the Company to monitor ongoing eligibility status, assist Participant’s through the redetermination process, address potential issues with eligibility in real time, and ~~people, the effects of which, to some extent, continue on federal, state and local economies, including~~track future renewal dates. However, as a result of ~~new virus variants that have resulted~~the aforementioned delays, the Company has experienced an increase in ~~renewed mask mandates in certain circumstances.~~

~~Expenses~~~~. The virus has and continues to impact older adults, especially those~~gaps of eligibility with ~~chronic illnesses, which describes our participants. The United States experienced supply chain issues with respect to personal protective equipment (“PPE”) and other medical supplies during~~redetermination applications. While the ~~height of the pandemic. Global logistics network challenges resulted in higher prices~~

~~Table of Contents~~

~~for medical supplies we require. While supply chain disruptions have adversely affected, and may~~participants continue to ~~adversely affect,~~receive care and remain enrolled with the Company during this time, the effect of such delays temporarily halts Medicaid revenue related to any closed application and simultaneously increases our ~~business and outlook, supply chain disruptions have improved~~risk of revenue recovery. In an effort to ~~almost pre-pandemic level during the course of the first half of fiscal 2023. As a result, prices for most medical supplies have normalized.~~

~~Labor market~~. The COVID-19 pandemic has and continues to exacerbate difficulties to hire additional healthcare professionals, causing certain of our centers to be understaffed or staffed with personnel that requires training. In fiscal year 2022, we experienced workforce and labor shortages, within all of our centers. This labor pressure has eased slightly during the six months ended December 31, 2022. While the labor pressure and related costs have eased slightly,mitigate these risks, the Company continues to ~~be affected by~~utilize State approved third-party eligibility partners to expedite applications, escalate delayed cases to State administrators, and pursue safe discharges for individuals who are truly ineligible. Being eight months into the public health emergency unwind period, there has not been a material effect on the Company’s financial statements or operations. The Company is seeing trends of aging report accounts and financial losses normalizing to pre-public health emergency levels. We expect these trends to continue for the remainder of fiscal year 2024.

Table of Contents

Labor market. The healthcare sector is currently experiencing a complex set of challenges in hiring additional professionals. We believe these challenges are a result of a combination of factors beyond the direct impact of the COVID-19 pandemic. Specifically, the demand for healthcare services has been steadily increasing due to an aging population and a greater focus on health and wellness in society. In addition, there are systemic challenges related to workforce training and the pipeline of qualified professionals, which have not kept pace with this growing demand. Furthermore, high inflation experienced during fiscal year 2023 and which has continued through fiscal year 2024 has increased the cost of living, and subsequently, wage pressure for healthcare professionals, with a shift towards an employee-centric market with an emphasis on competitive compensation, flexibility and professional growth opportunities, which has contributed to an increasingly competitive labor market. In an effort to mitigate the effects of these challenges, we have adopted strategies to offer competitive compensation packages. Partially as a result of increased competition and other market trends, in ~~the labor market~~conjunction with increased staffing related to compliance and ~~market adjustments to increase retention and improve~~remediation efforts in our ~~ability to hire. These adjustments contributed, in part, to~~centers, there has been an increase in the cost of care for the six months ended December 31, 2022, further impacted by additional staffing related to compliance and remediation efforts. This increase in conjunction with higher headcount has contributed to increased cost of care for the six months ended December 31, 20222023 compared to the ~~six months ended December 31, 2021~~comparable period last year, as discussed in ~~“Results~~"Results of ~~Operations”~~Operations" below.

Additionally, on October 13, 2023, California passed into law California Senate Bill No. 525 ("SB 525"), which raises the minimum wage for many California healthcare workers, effective as of June 1, 2024. Although PACE centers are not covered by SB 525, many of our contractors and other third-party providers are impacted by SB 525, and they may renegotiate agreements with our centers to cover their increased labor costs. Additionally, competition with other healthcare providers who are required to increase wages under SB 525 could materially increase our labor costs. We will continue to ~~assess key roles~~evaluate the impact of this legislation on our business.

Finally, on October 27, 2023, following a demand from a labor union for the Company to recognize it as the collective bargaining representative of the nurses and ~~benchmarks~~certified nurse assistants in our Pennsylvania centers, we filed a petition with the National Labor Relations Board to ~~market while monitoring trends~~conduct two elections. The National Labor Relations Board conducted the elections on December 6, 2023, at which the nurses and certified nurse assistants in our Pennsylvania centers voted to unionize. These employees represent approximately 1% of our total workforce. Collective bargaining has not yet commenced. While we cannot predict the terms or timing of any resulting collective bargaining agreement, we currently do not expect the impact from any such future negotiated collective bargaining agreements and costs for unionized employees to have a material effect on our costs of labor ~~market.~~

or operations. However, we cannot predict whether other employees will follow a similar course of action.

For additional information on the various risks posed by macroeconomic events, regulation, and ~~the ongoing COVID-19 pandemic,~~employee matters, please see the section entitled “Risk Factors” included in Part I, Item 1A of our ~~2022 10-K.~~

2023 10-K and in Part II, Item 1A of this Form 10-Q.

Key Factors Affecting Our Performance

Our historical financial performance has been, and we expect our financial performance in the future to be, driven by the following factors:

●

~~Our ability to effectively implement remediation efforts in our centers as a result of our recent audits.~~ ~~The Company’s priority is to remediate the deficiencies raised in the audit processes in California, Colorado and New Mexico.~~

•Our ability to effectively implement post-sanction remediation efforts in our centers as a result of our recent audits and maintain high quality of regulatory compliance. The Company’s priority is to continue to remediate the deficiencies raised in audit processes (including recent and new audits) and to implement post-sanction corrective actions, where required, as well as maintain high quality of regulatory compliance in all its centers. As part of its actions to do so, the Company has worked with the appropriate authorities to make the necessary changes within the Company to increase care coordination and care documentation among our centers, including working to fill critical personnel gaps at our centers, standardizing the process of our Interdisciplinary Care Teams (“IDTs”), strengthening our home care network and reliability, improving timelines of scheduling and coordinating care with providers outside our centers, among others. See “Audit Processes and Remediation Efforts” below.

●

~~Our participants.~~ We focus on providing all-inclusive care to frail, high-cost, dual-eligible seniors. We directly contract with government payors, such as Medicare and Medicaid, through PACE and receive a capitated risk-adjusted payment to manage the totality of a participant’s medical care across all settings. InnovAge manages participants that are, on average, more complex and medically fragile than other Medicare-eligible patients, including those in Medicare Advantage (“MA”) programs. As a result, we receive larger payments for our participants compared to MA participants. This is driven by two factors: (i) we manage a higher acuity population, with an average risk adjustment factor (“RAF”) score of 2.31 based on InnovAge data as of December 31, 2022; and (ii) we manage Medicaid spend in addition to Medicare. Our participants are managed on a capitated, or at-risk basis, where InnovAge is financially responsible for all of participant medical costs. Our comprehensive care model and globally capitated payments are designed to cover participants from enrollment until the end of life, including coverage for participants requiring hospice and palliative care. For dual-eligible participants, we receive per member, per month (“PMPM”) payments directly from Medicare and Medicaid, which provides recurring revenue streams and significant visibility into our revenue. The Medicare portion of our capitated payment is risk-based on the underlying medical conditions and frailty of each participant.

●

~~Our ability to grow enrollment and capacity within existing centers.~~ We believe all seniors should have access to the type of all-inclusive care offered by the PACE model. Several factors can affect our ability to grow enrollment and capacity within existing centers, including sanctions issued by regulators. Even though enrollment sanctions have been released in the State of Colorado, our ability to enroll Medicaid recipients, which is required to enroll seniors with both Medicare and Medicaid, remain suspended at our Sacramento, California center by the Department of Health Care Services (“DHCS”) of the State of California.

~~Table of Contents~~

●

~~Our ability to maintain high participant satisfaction and retention.~~ We achieved a 79% participant satisfaction rating as of October 1, 2022 and average participant tenure was 3.2 years as of December 31, 2022, measured as tenure from enrollment to disenrollment, among our centers that have been operated by us for at least five years. Furthermore, we experience low levels of voluntary disenrollment, averaging 5.7% annually over the last three fiscal years. Approximately 75% of our historical disenrollments have been involuntary, due primarily to participant death or otherwise due to participants moving out of our service areas.

●

~~Effectively managing the cost of care for our participants~~. We receive capitated payments to manage the totality of a participant’s medical care across all settings. Because our participants are among the most frail and medically complex individuals in the U.S. healthcare system, our external provider costs and cost of care, excluding depreciation and amortization, represented approximately 87% of our revenue in the six months ended December 31, 2022. While we are liable for potentially large medical claims, our care model focuses on delivering high-quality medical care in cost efficient, community-based settings as a means of avoiding costly inpatient and outpatient services. However, our participants retain the freedom to seek care at sites of their choice, including hospitals and emergency rooms; we do not restrict participant access to care.

●

~~Center-level Contribution Margin~~. As we serve more participants in existing centers, we leverage our fixed cost base at those centers and the value of a center to our business increases over time. The enrollment sanctions in Sacramento, California and Colorado limited our ability to grow our participant census and impact Center-level Contribution Margin in fiscal 2022 and the first half of fiscal 2023.

●

~~Our ability to expand via acquisition or de novo centers within existing and new markets.~~ Several factors can affect our ability to open de novo centers, including sanctions issued by regulators. On January 7, 2022, DHCS of the State of California notified us that it was suspending the State’s previously provided assurances that it would enter into a PACE program agreement with the Company (State Attestations) with respect to de novo centers in the State of California until such time as the corrective action plans (“CAPs”) and the remediation and validation processes for our Sacramento center have been successfully completed and the enrollment sanctions are lifted. In addition, on February 9, 2022, we received notice from the Cabinet for Health and Family Services of the State of Kentucky informing us that they no longer intend to enter into an agreement with us to be a PACE provider in the State of Kentucky. On February 14, 2022, CMS denied our application to develop the previously announced PACE center in Terre Haute, Indiana, which was projected to open in fiscal year 2024 based on deficiencies detected during CMS’ 2021 audits of our Sacramento and Colorado PACE programs. In addition, we have committed to CMS and the Agency for Healthcare Administration in the State of Florida, that we will proactively pause remaining steps with respect to de novo centers to focus on remediating deficiencies raised in the audit processes.

●

~~Execute tuck-in acquisitions.~~ From fiscal year 2019 through fiscal year 2021, we acquired and integrated three PACE organizations, expanding our InnovAge Platform to one new state and four new markets through those acquisitions. We are disciplined in our approach to acquisitions and have executed multiple types of transactions, including turnarounds and non-profit conversions. Historically, when integrating acquired programs, we worked closely with key constituencies, including local governments, health systems and senior housing providers, to enable continuity of high-quality care for participants. Once restrictions on our ability to open de novo centers are lifted or resolved, we intend to resume execution of tuck-in acquisitions.

●

~~Contracting with government payors~~. Our economic model relies on our capitated arrangements with government payors, namely Medicare and Medicaid. We view the government not only as a payor but also as a key partner in our efforts to expand into new geographies and access more participants in our existing markets. Maintaining, supporting and growing these relationships in existing markets as well as new geographies, is critical to our long-term success.

●

~~Investing to support growth~~. We intend to continue investing in our centers, value-based care model, and sales and marketing organization to support long-term growth. We expect our expenses to increase in absolute dollars for the foreseeable future to support our growth and due to additional costs we are incurring

~~Table of Contents~~

and expect to incur as a public company, including expenses related to compliance with the rules and regulations of the SEC and the listing standards of Nasdaq, additional corporate and director and officer insurance, investor relations and increased legal, audit, reporting and consulting fees. We also expect to incur additional expenses for the foreseeable future in connection with current and future audits to our centers, remediation plans and current and potential legal and regulatory proceedings. We plan to invest in future growth judiciously and maintain focus on managing our results of operations. Accordingly, in the short term we expect the activities noted above to increase our expenses as a percentage of revenue, but in the longer term, we anticipate that these investments will positively impact our business and results of operations.

●

~~Seasonality of our business~~. Our operational and financial results, including medical costs and per-participant revenue true-ups, will experience some variability depending upon the time of year in which they are measured. Medical costs vary most significantly as a result of (i) the weather, with certain illnesses, such as the influenza virus, being more prevalent during colder months of the year, which generally increases per-participant costs and (ii) the number of business days in a period, with shorter periods generally having lower medical costs all else equal. Per-participant revenue true-ups represent the difference between our estimate of per-participant capitation revenue to be received and actual revenue received by CMS, which is based on CMS’s determination of a participant’s Risk Adjustment Factor score as measured twice per year and is based on the evolving acuity of a participant. Based on the difference between our estimate and the final determination from CMS, we may receive incremental true up revenue or be required to repay certain amounts. Historically, these true-up payments typically occur between May and August, but the timing of these payments is determined by CMS, and we have neither visibility into nor control over the timing of such payments.

~~Audit Processes and Remediation Efforts~~

We are routinely subject to, and will continue to be subject to, various governmental inspections, reviews and audits. Set forth below is a summary of the ongoing audits at our centers and updates on such audit processes.

~~Colorado.~~ In December 2021, each of CMS and the Colorado Department of Health Care Policy & Financing (“HCPF”) suspended new enrollments at the Company’s Colorado centers, based on deficiencies related to participant provision of services detected in the joint audit initiated in May and June 2021. On January 23, 2023, both CMS and HCPF released the enrollment sanctions for all Colorado centers. CMS and HCPF require that we conduct post-sanction corrective action and monitoring activities to address any issues identified during the validation audits.

~~California.~~ ~~On May 10, 2021, CMS began an audit of our Sacramento, California center. In~~September 2021, CMS suspended new enrollments at our Sacramento center based on deficiencies detected in the audit related to participant provision of services. In that same month, we were further notified that the DHCS had reached the same determination. In October 2021, we submitted a CAP to each of these agencies and began executing the CAPs. Effective November 21, 2022, CMS released the enrollment sanction for Medicare-eligible participants. The DHCS has not lifted the state sanction. The DHCS audit outcome determines our ability to enroll Medicaid recipients, which is required to enroll seniors with both Medicare and Medicaid. Timing and results of validation from DHCS are uncertain, and there can be no assurance that the agency will agree with us or release us from sanction.

~~In January 2022, DHCS notified us that it was suspending the State Attestations with respect to de novo centers in the State of California until such time as its enrollment sanctions are lifted.~~

In March 2022, CMS and DHCS began separate audits of our San Bernardino, California center. On January 11, 2023, CMS closed its audit. There has been no additional activity related to the DHCS audit; however, DHCS has not officially closed the audit.

~~New Mexico.~~ ~~In November 2021, CMS began an audit of our Albuquerque, New~~Mexico center. In July 2022, CMS verbally notified us that no enforcement actions will be taken, and in October 2022, CMS issued a final audit report. To address the deficiencies related to participant provision of services identified in the audit, we implemented iCARs and CARs and are currently working with CMS on the audit close out process.

~~Table of Contents~~

~~Kentucky, Indiana and Florida~~. The States of Kentucky and Indiana have taken actions to suspend our ability to open de novo centers in those states, and we have committed to regulatory agencies in the State of Florida, that we will proactively pause remaining steps with respect to planned de novo centers in that state.

~~The Company’s priority is to remediate the deficiencies raised in the audit processes and to return to growth as a company, both for the short- and long-term. We continue to work~~ with the appropriate authorities to make the necessary changes within the Company to ~~increase~~improve care coordination and care documentation among our centers, including working to fill critical personnel gaps at our centers, standardizing the process of our Interdisciplinary Care Teams (“IDTs”), strengthening our home care network and reliability, improving timelines of scheduling and coordinating care with providers outside our centers, among others.

•Our participants. We focus on providing all-inclusive care to frail, high-cost, dual-eligible seniors. We directly contract with government payors, such as Medicare and Medicaid, through PACE and receive a capitated risk-adjusted payment to manage the totality of a participant’s medical care across all settings. InnovAge manages participants that are, on average, more complex and medically fragile than other Medicare-eligible patients, including those in Medicare Advantage (“MA”) programs. As a result, we receive larger payments for our participants compared to MA participants. This is driven by two factors: (i) we manage a higher acuity population, with an average risk adjustment factor (“RAF”) score of 2.42 based on InnovAge data as of December 31, 2023; and (ii) we manage Medicaid spend in addition to Medicare. Our

Table of Contents

participants are managed on a capitated, or at-risk basis, where InnovAge is financially responsible for all of participant medical costs. Our comprehensive care model and globally capitated payments are designed to cover participants from enrollment until the end of life, including coverage for participants requiring hospice and palliative care. For dual-eligible participants, we receive per member, per month (“PMPM”) payments directly from Medicare and Medicaid, which provides recurring revenue streams and significant visibility into our revenue. The Medicare portion of our capitated payment is risk-based, taking into account the underlying medical conditions and frailty of each participant. We continue to work on expanding payer capabilities so that our revenue more accurately reflects the acuity of the populations we serve.

•Our ability to grow enrollment and capacity within existing centers.

We believe all seniors should have access to the type of all-inclusive care offered by the PACE model. Several factors can affect our ability to grow enrollment and capacity within existing centers, including sanctions issued by regulators, such as the ones we were subject to in our Sacramento, California and Colorado centers.

•Our ability to maintain high participant satisfaction and retention. We achieved a 86% participant satisfaction rating as of September 30, 2023, measured as composite of participant satisfaction across ten categories, and average participant tenure was 3.2 years as of December 31, 2023, measured as tenure from enrollment to disenrollment, among our centers that have been operated by us for at least five years. Furthermore, we experience low levels of voluntary disenrollment, averaging 5.9% annually over the last three fiscal years. Approximately 71% of our historical disenrollments have been involuntary, due primarily to participant death or otherwise due to participants moving out of our service areas.

•Effectively managing the cost of care for our participants. We receive capitated payments to manage the totality of a participant’s medical care across all settings. Our participants are among the most frail and medically complex individuals in the U.S. healthcare system, and average acuity rises with the passage of time. The risk pool of our population became more acute in fiscal year 2023 as we were not able to replenish our population mix with newer, lower-acuity participants as a result of State sanctions, and as a result, our external provider costs and cost of care, excluding depreciation and amortization, represented approximately 84% of our revenue in the six months ended December 31, 2023. While we are liable for potentially large medical claims, our care model focuses on delivering high-quality medical care in cost efficient, community-based settings as a means of avoiding costly inpatient and outpatient services. However, our participants retain the freedom to seek care at sites of their choice, including hospitals and emergency rooms; we do not restrict participant access to care.

•Center-level Contribution Margin. As we serve more participants in existing centers, we leverage our fixed cost base at those centers and the value of a center to our business increases over time. The enrollment sanctions in Sacramento, California and Colorado limited our ability to grow our participant census and impacted Center-level Contribution Margin in fiscal 2022 and the first half of fiscal 2023. We were fully released from those sanctions in Colorado in January 2023 and in California in May 2023. The Company continues post-sanction monitoring, and is currently able to enroll new participants at all of its centers. For the six months ended December 31, 2023, census has grown 1.2% compared to the six months ended December 31, 2022.

•Our ability to expand via de novo centers within existing and new markets. Several factors can affect our ability to open de novo centers, including sanctions issued by regulators, such as the ones imposed on our Sacramento, California and Colorado centers in 2021. As a result of such sanctions, we were precluded from, or voluntarily suspended efforts to, open de novo centers.

On January 1, 2024, we opened a PACE center in Tampa, Florida, which has opened enrollment to various surrounding counties, and continue our efforts to obtain the licensure required to open a PACE center in Orlando, Florida.

All new PACE centers are subject to annual federal and state audits for the first three years after opening. In October 2023, CMS and the California Department of Health Care Services (“DHCS) conducted a joint routine audit of our Sacramento center. On December 27, 2023, we received the final audit report from CMS for which we submitted a routine corrective action plan (CAP) that follows every audit. On January 22, 2024, CMS approved that CAP. On January 23, 2024, DHCS notified us of their preliminary audit findings at our Sacramento center and that, based on concerns that it had been alerted to, it will be conducting a medical

Table of Contents
review of our San Bernardino center. In response to both of these matters, DHCS notified us that it is suspending its attestations in support of the planned de novo center in Downey and the recently acquired planned de novo center in Bakersfield. On February 1, 2024, we received the final audit results from DHCS notifying us of identified deficiencies at our Sacramento center, some of which fall under the same categories as those that formed the basis of the enrollment freeze in 2021. While these de novo centers are precluded from opening at this time, DHCS notified us that it would consider restoring the State Attestations upon our successful remediation of the deficiencies raised in our Sacramento center and its completion of the medical review (and any potential resultant remediation that may be required) in our San Bernardino center. We believe we have in place the policies, processes and systems to correct the identified deficiencies as we did in connection with the 2021 enrollment freeze.
•Execute tuck-in acquisitions. From fiscal year 2019 through fiscal year 2021, we acquired and integrated three PACE organizations, expanding our InnovAge Platform to one new state and four new markets through those acquisitions. Additionally, in the second fiscal quarter of 2024, we completed an acquisition of two PACE programs in California from ConcertoCare, which included one operating center in the Crenshaw neighborhood of Los Angeles and a second program in the process of its application for licensure in Bakersfield, California. We remain disciplined in our approach to acquisitions and in the past have executed multiple types of transactions, including turnarounds and non-profit conversions. When integrating acquired programs, we work closely with key constituencies, including local governments, health systems and senior housing providers, to enable continuity of high-quality care for participants.
•Contracting with government payors. Our economic model relies on our capitated arrangements with government payors, namely Medicare and Medicaid. We view the government not only as a payor but also as a key partner in our efforts to expand into new geographies and access more participants in our existing markets. Maintaining, supporting and growing these relationships in existing markets as well as new geographies, is critical to our long-term success.
•Investing to support growth. We intend to continue investing in our centers, value-based care model, and sales and marketing organization to support long-term growth. We expect our expenses to increase in absolute dollars for the foreseeable future to support our growth and due to additional costs we are incurring or expect to incur in connection with our current and future audits to our centers, our post-audit remediation plans and current and potential legal and regulatory proceedings. We plan to invest in future growth judiciously and maintain focus on managing our results of operations. We are building capabilities to increase our sophistication as a payor to drive clinical value, improve outcomes, and manage cost trends. Accordingly, in the short term, we expect the activities noted above to increase our expenses as a percentage of revenue, but in the longer term, we anticipate that these investments will positively impact our business and results of operations.
•Seasonality of our business. Our operational and financial results, including medical costs and per-participant revenue true-ups, experience some variability depending upon the time of year in which they are measured. Medical costs vary most significantly as a result of (i) the weather, with certain illnesses, such as the influenza virus, being more prevalent during colder months of the year, which generally increases per-participant costs, specifically in 2024, we expect to see some increase in inpatient and short stay nursing home utilization as well as increased acuity of our participant mix; and (ii) the number of business days in a period, with shorter periods generally having lower medical costs, all else equal. Per-participant revenue true-ups represent the difference between our estimate of per-participant capitation revenue to be received and actual revenue received by CMS, which is based on CMS’s determination of a participant’s RAF score as measured twice per year and is based on the evolving acuity of a participant. Where there is a difference between our estimate and the final determination from CMS, we may receive incremental true-up revenue or be required to repay certain amounts. Historically, these true-up payments typically occur between May and August, but the timing of these payments is determined by CMS, and we have neither visibility into nor control over the timing of such payments.
32
Table of Contents

Components of Results of Operations

Revenue

~~Revenue~~

Capitation Revenue. In order to provide comprehensive services to manage the totality of a participant’s medical care across all settings, we receive fixed or capitated fees per participant that are paid monthly by Medicare, Medicaid, Veterans Affairs (“VA”) and private pay sources.

Medicaid and Medicare capitation revenues are based on PMPM capitation rates under the PACE program. The PACE state contracts between us and the respective state Medicaid administering agency are amended annually each June 30 in all states other than California and Pennsylvania, which contract on a calendar-year basis. New amendments have been executed for the periods (i) January 1, 2021 through December 31, 2025 for California and (ii) July 1, 2022 through June 30, 2023 for all other states, except Pennsylvania, for which weWe are currently operating in good standing under ~~the 2020 amended agreement while the agency finalizes its current amendment.~~each of our PACE state contracts. For a discussion of our revenue recognition policies, please see Critical Accounting Estimates below and Note 2 “Summary of Significant Accounting Policies” to our consolidated financial statements included in our ~~2022~~2023 10-K.

Other Service Revenue. Other service revenue primarily consists of revenues derived from fee-for-service arrangements, state food grants, rent revenues and management fees. Prior to June 30, 2022, we generated fee-for-service revenue from providing home-care services to non-PACE patients in their homes, for which we billed the patient or their insurance plan on a fee-for-service basis. We no longer offer in-home care ~~services.~~services to non-PACE participants. For a discussion of our revenue recognition policies, please see Critical Accounting Estimates below and Note 2, ~~“Summary~~“Summary of Significant Accounting Policies” to our consolidated financial statements included in our ~~2022~~2023 10-K.

Operating Expenses

External Provider Costs. External provider costs consist primarily of the costs for medical care provided by non-InnovAge providers. We separate external provider costs into four categories: inpatient (e.g., hospital), housing (e.g., assisted living and skilled nursing facility), outpatient and pharmacy. In aggregate, external provider costs represent the largest portion of our expenses.

Cost of Care, Excluding Depreciation and Amortization. Cost of care, excluding depreciation and amortization, includes the costs we incur to operate our care delivery model. This includes costs related to salaries, wages and benefits for IDT and other center-level staff, participant transportation, medical supplies, occupancy, insurance and other operating costs. IDT employees include medical doctors, registered nurses, social workers, physical, occupational, and speech therapists, nursing assistants, and transportation workers. Other center-level employees include clinic managers, dieticians, activity assistants and certified nursing assistants. Cost of care excludes any expenses associated with sales and marketing activities incurred at a local level as well as any allocation of our corporate, general and administrative expenses. A portion of our cost of care, including our employee-related costs, is directly related to the number of participants cared for in a center. The remainder of our cost of care is fixed relative to the number of participants we serve, such as occupancy and insurance expenses. As a result, as revenue increases due to census growth, cost of care, excluding depreciation and amortization, moderately decreases as a percentage of revenue. As we open new centers, we expect cost of care, excluding depreciation and amortization, to increase in absolute dollars due to higher census and facility related costs.

Sales and Marketing. Sales and marketing expenses consist of employee-related expenses, including salaries, commissions, and employee benefits costs, for all employees engaged in marketing, sales, community outreach and

~~Table of Contents~~

sales support. These employee-related expenses capture all costs for both our field-based and corporate sales and marketing teams. Sales and marketing expenses also include local and centralized advertising costs, as well as the infrastructure required to support our marketing efforts. We expect these costs to increase in absolute dollars over time as we ~~continue to~~ grow our participant census. We evaluate our sales and marketing expenses relative to our participant growth and will invest more heavily in sales and marketing from time-to-time to the extent we believe such investment can accelerate our growth without negatively affecting profitability.

Corporate, General and Administrative. Corporate, general and administrative expenses include employee-related expenses, including salaries and related costs. In addition, general and administrative expenses include all corporate technology and occupancy costs associated with our corporate office. We expect our general and administrative expenses to increase in absolute dollars due to the additional legal, accounting, insurance, investor relations and other costs that we incur as a public company, as well as other costs associated with compliance and continuing to grow our business. However, we anticipate general and administrative expenses to decrease as a percentage of revenue over the long term,

Table of Contents

although such expenses may fluctuate as a percentage of revenue from period to period due to the timing and amount of these expenses.

Depreciation and Amortization. Depreciation and amortization expenses are primarily attributable to our buildings and leasehold improvements and our equipment and vehicles. Depreciation and amortization are recorded using the straight-line method over the shorter of estimated useful life or lease terms, to the extent the assets are being leased.

For more information relating to the components of our results of operations, see Results of Operations below and Note 2 “Summary of Significant Accounting Policies” to our consolidated financial statements included in our ~~2022~~2023 10-K.

~~Table of Contents~~

Results of Operations

The following table sets forth our consolidated results of operations for the periods presented:


	Three Months Ended December 31,				Six Months Ended December 31,
in thousands	2023		2022		2023		2022
Revenues
Capitation revenue	$	188,561	$	167,140	$	370,734	$	338,071
Other service revenue	337		316		648		603
Total revenues	188,898		167,456		371,382		338,674
Expenses
External provider costs	100,964		93,507		200,322		189,744
Cost of care, excluding depreciation and amortization	54,321		51,376		109,570		104,933
Sales and marketing	5,859		3,774		11,237		8,187
Corporate, general and administrative	25,249		28,817		54,197		58,999
Depreciation and amortization	4,290		3,662		8,559		7,095
Total expenses	190,683		181,136		383,885		368,958
Operating Loss	$	(1,785)	$	(13,680)	(12,503)		(30,284)

Other Income (Expense)
Interest expense, net	(935)		(223)		(1,596)		(826)
Other income	874		444		1,517		480
Other expense	(1,882)		—		(1,882)		—
Total other expense	(1,943)		221		(1,961)		(346)
Loss Before Income Taxes	(3,728)		(13,459)		(14,464)		(30,630)
Provision (Benefit) for Income Taxes	93		(2,912)		319		(6,383)
Net Loss	$	(3,821)	$	(10,547)	$	(14,783)	$	(24,247)
Less: net loss attributable to noncontrolling interests	(374)		(754)		(1,032)		(1,381)
Net Loss Attributable to InnovAge Holding Corp.	$	(3,447)	$	(9,793)	$	(13,751)	$	(22,866)

Revenues


	Three Months Ended December 31,				Change				Six Months Ended December 31,				Change
	2023		2022		$		%		2023		2022		$		%
in thousands
Capitation revenue	$	188,561	$	167,140	$	21,421	12.8	%	$	370,734	$	338,071	$	32,663	9.7	%
Other service revenue	337		316		21		6.6	%	648		603		45		7.5	%
Total revenues	$	188,898	$	167,456	$	21,442	12.8	%	$	371,382	$	338,674	$	32,708	9.7	%

Table of Contents

Three Months Ended

Six Months Ended

December 31,

December 31,
in thousands

2022

2021

2022

2021
Revenues








Capitation revenue

$
167,140

$
174,964

$
338,071

$
347,518
Other service revenue

316

386

603

902
Total revenues

167,456

175,350

338,674

348,420
Expenses








External provider costs

93,507

91,033

189,744

181,045
Cost of care, excluding depreciation and amortization

51,376

42,911

104,933

83,639
Sales and marketing

3,774

6,679

8,187

12,972
Corporate, general and administrative

28,817

28,482

58,999

49,566
Depreciation and amortization

3,662

3,292

7,095

6,585
Total expenses

181,136

172,397

368,958

333,807
Operating Income (Loss)

$
(13,680)

$
2,953

$
(30,284)

$
14,613

Other Income (Expense)








Interest expense, net

(223)

(674)

(826)

(1,221)
Other income (expense)

444

28

480

(465)
Total other expense

221

(646)

(346)

(1,686)
Income (Loss) Before Income Taxes

(13,459)

2,307

(30,630)

12,927
Provision (Benefit) for Income Taxes

(2,912)

1,201

(6,383)

4,197
Net Income (Loss)

$
(10,547)

$
1,106

$
(24,247)

$
8,730
Less: net loss attributable to noncontrolling interests

(754)

(217)

(1,381)

(279)
Net Income (Loss) Attributable to InnovAge Holding Corp.

$
(9,793)

$
1,323

$
(22,866)

$
9,009

~~Revenues~~

Three Months Ended






Six Months Ended






December 31,

Change

December 31,

Change


2022

2021

$

%

2022

2021

$

%
in thousands

















Capitation revenue

$
167,140

$
174,964

$
(7,824)

(4.5)
%

$
338,071

$
347,518

$
(9,447)

(2.7)
%
Other service revenue

316

386

(70)

(18.1)
%

603

902

(299)

(33.1)
%
Total revenues

$
167,456

$
175,350

$
(7,894)

(4.5)
%

$
338,674

$
348,420

$
(9,746)

(2.8)
%

Capitation revenue. Capitation revenue was $188.6 million for the three months ended December 31, 2023 an increase of $21.4 million, or 12.8%, compared to $167.1 million for the three months ended December 31, ~~2022, a decrease of $7.8 million, or 4.5%, compared to $175.0 million for the three months ended December 31, 2021.~~2022. This ~~decrease~~increase was driven by a ~~8.1% decrease in member months partially offset by a 4.0%~~$15.8 million, or 9.1%, increase in capitation ~~rates. The decrease~~rates coupled with $5.6 million, or 3.4%, increase in member ~~months is primarily due to disenrollments and our inability to enroll new participants at our Sacramento, California and Colorado centers as a result of the sanctions.~~months. The increase in capitation rates was primarily driven by an(i) a 7.0% annual increase in Medicaid capitation rates as determined by the States and (ii) an 11.8% increase in Medicare capitation rates as a result of increased risk score and county rates ~~partially offset by~~coupled with a one-time true up outside of the ~~reinstatement of sequestration.~~

regular payment cycle. The increase in member months is primarily due to the release from sanctions at our Colorado and Sacramento centers.

Capitation revenue was $370.7 million for the six months ended December 31, 2023, an increase of $32.7 million, or 9.7% compared to $338.1 million for the six months ended December 31, ~~2022,~~2022. This increase was driven by a ~~decrease of $9.4~~$28.7 million, or ~~2.7%~~8.4%, ~~compared to $347.5~~increase in capitation rates coupled with a $3.9 million, or 1.2%, increase in member months. The increase in capitation rates include a 6.9% annual increase in Medicaid rates and a 10.3% increase in Medicare rates.

Operating Expenses


	Three Months Ended December 31,				Change				Six Months Ended December 31,				Change
	2023		2022		$		%		2023		2022		$		%
in thousands
External provider costs	$	100,964	$	93,507	$	7,457	8.0%		$	200,322	$	189,744	$	10,578	5.6%
Cost of care (excluding depreciation and amortization)	54,321		51,376		2,945		5.7%		109,570		104,933		4,637		4.4%
Sales and marketing	5,859		3,774		2,085		55.2	%	11,237		8,187		3,050		37.3	%
Corporate, general, and administrative	25,249		28,817		(3,568)		(12.4)%		54,197		58,999		(4,802)		(8.1)%
Depreciation and amortization	4,290		3,662		628		17.1%		8,559		7,095		1,464		20.6%
Total operating expenses	$	190,683	$	181,136	$	9,547			$	383,885	$	368,958	$	14,927

External provider costs. External provider costs were $101.0 million for the ~~six~~three months ended December 31, ~~2021. This decrease was driven by a 6.9% decrease in member months partially offset by a 4.4%~~2023, an increase ~~in capitation rates, primarily due~~of $7.5 million, or 8.0%, compared to ~~the factors discussed above.~~

~~Table of Contents~~

~~Operating Expenses~~

Three Months Ended






Six Months Ended






December 31,

Change

December 31,

Change

2022

2021

$

%

2022

2021

$

%
in thousands

















External provider costs

$
93,507

$
91,033

$
2,474

2.7
%

$
189,744

$
181,045

$
8,699

4.8
%
Cost of care (excluding depreciation and amortization)

51,376

42,911

8,465

19.7
%

104,933

83,639

21,294

25.5
%
Sales and marketing

3,774

6,679

(2,905)

(43.5)
%

8,187

12,972

(4,785)

(36.9)
%
Corporate, general, and administrative

28,817

28,482

335

1.2
%

58,999

49,566

9,433

19.0
%
Depreciation and amortization

3,662

3,292

370

11.2
%

7,095

6,585

510

7.7
%
Total operating expenses

$
181,136

$
172,397

$
8,739

$
368,958

$
333,807

$
35,151

~~External provider costs.~~ ~~External provider costs were~~ $93.5 million for the three months ended December 31, ~~2022, an increase of $2.5 million, or 2.7%, compared to $91.0 million for the three months ended December 31, 2021.~~2022. The increase was primarily driven by an increase of ~~$9.9~~$4.3 million, or ~~11.8%~~4.4%, in cost per participant coupled with an increase of $3.2 million, or 3.4% in member months. The increase in cost per participant was primarily driven by an annual increase in pharmacy cost, an increase in assisted living utilization and unit cost, and an increase in outpatient services utilization. This was partially offset by a decrease in permanent nursing facility utilization.

External provider costs were $200.3 million for the six months ended December 31, 2023, an increase of ~~$7.4~~$10.6, or 5.6%, compared to $189.7 for the six months ended December 31, 2022. This increase was primarily driven by an increase of $8.4 million, or ~~8.1%~~4.4%, in cost per participant coupled with an increase of $2.2 million, or 1.2%, in member months. The increase in cost per participant was primarily driven by ~~a $8.3 million~~an annual increase ~~associated with increased housing~~in pharmacy cost, an increase in assisted living utilization and unit cost, ~~per day as mandated by certain states.~~

~~External provider costs were $189.7 million for the six months ended December 31, 2022,~~and an increase ~~of $8.7 million, or 4.8%, compared to $181.0 million for the six months ended December 31, 2021. The increase~~in outpatient services utilization. This is ~~primarily driven by an increase of $21.1 million, or 12.5%, in cost per participant~~ partially offset by a decrease ~~of $12.4 million, or 6.9%,~~ in ~~member months. The increase in cost per participant is primarily driven by a $14.7 million increase associated with increased housing utilization~~permanent and ~~cost per day as mandated by certain states.~~

short stay nursing facility utilization.

Cost of care (excluding depreciation and amortization). Cost of care (excluding depreciation and amortization) expense was $54.3 million for the three months ended December 31, 2023, an increase of $2.9 million, or 5.7%, compared to $51.4 million for the three months ended December 31, 2022, ~~an increase of $8.5 million, or 19.7%, compared to $42.9 million for the three months ended December 31, 2021,~~ primarily due to an increase of ~~$11.9~~$1.2 million, or ~~30.0%~~2.3%, in cost per participant ~~partially offset by a decrease~~coupled with an increase of ~~$3.5~~$1.7 million, or ~~8.1%~~3.4%, in member months. The increase was primarily driven by (i) a ~~$5.4~~$3.1 million increase in salaries, wages and benefits associated with increased headcount and higher wage rates, ~~due to the ongoing competitive labor market,~~ (ii) $0.9 million in increased building maintenance and security, and (iii) $0.4 million in increased fleet expense and contract transportation a result of an increase in center attendance and an increase in external appointments, partially offset by $1.0 million reduction in third party audit and compliance ~~support, and (iii) $0.9 million in increased fleet and contract transportation as a result of higher average daily attendance, increase in external appointments, and higher fuel costs.~~

support.

Cost of care (excluding depreciation and amortization) expense was $109.6 million for the six months ended December 31, 2023, an increase of $4.6 million, or 4.4%, compared to $104.9 million for the six months ended December 31, 2022, ~~an increase of $21.3 million, or 25.5%, compared to $83.6 million for the six months ended December 31, 2021,~~ primarily due to an increase of ~~$27.0~~$3.4 million, or ~~34.7%~~3.2%, in cost per participant ~~partially offset by a decrease~~coupled with an increase of ~~$5.7~~$1.2 million, or ~~6.9%~~1.2%, in member months. The increase was primarily driven by (i) a ~~$13.2~~$4.5 million increase in salaries, wages and benefits associated with increased headcount and ~~higher~~ wage ~~rates due to the ongoing competitive labor market,~~rate, (ii) ~~$2.1~~$1.5 million in increased building maintenance and security, and (iii) $1.8 million in increased fleet expense as a result of an increase in center attendance and an increase in external appointments, partially offset by $2.5 million reduction in third party audit and compliance ~~support, (iii) $2.2 million in increased fleet and contract transportation as a result~~support.

Table of ~~higher average daily attendance, increase in external appointments, and higher fuel costs, and (iv) $0.9 million in de novo costs due primarily to rent expense.~~

Contents

Sales and marketing. Sales and marketing expenses were $5.9 million for the three months ended December 31, 2023, an increase of $2.1 million, or 55.2%, compared to $3.8 million for the three months ended December 31, 2022, ~~a decrease of $2.9 million, or 43.5%, compared to $6.7 million for the three months ended December 31, 2021,~~ primarily due to ~~a (i) $1.3 million reduction in~~increased marketing spend and ~~$0.6 million reduction in costs associated with fewer~~ headcount ~~within the sales department, both~~ as a result of ~~sanctions~~the sanction release in our Colorado and Sacramento ~~centers and (ii) a $0.8 million reduction in sales commission expense due to the deferral of commissions.~~

centers.

Sales and marketing ~~expenses~~expense were $11.2 million for the six months ended December 31, 2023, an increase of $3.1 million, or 37.3%, compared to $8.2 million for the six months ended December 31, 2022, ~~a decrease of $4.8 million, or 36.9%, compared to $13.0 million for the six months ended December 31, 2021,~~ primarily due to ~~a $2.6 million~~

~~Table of Contents~~

~~reduction in~~increased marketing spend and ~~$1.2 million reduction in costs associated with fewer~~ headcount ~~within the sales department, both~~ as a result of ~~sanctions~~the sanction release in our Colorado and Sacramento ~~centers and (ii) a $0.8 million reduction in sales commissions expense due to the deferral of commissions.~~

centers.

Corporate, general and administrative. Corporate, general and administrative expenses were $25.2 million for the three months ended December 31, 2023, a decrease of $3.6 million, or 12.4%, compared to $28.8 million for the three months ended December 31, ~~2022, an increase of $0.3 million, or 1.2%, compared to $28.5 million for the three months ended December 31, 2021.~~2022. The ~~increase~~decrease was primarily due to (i) a ~~$1.9~~$2.9 million reduction in third party legal expense, (ii) a $0.6 million reduction in insurance expense, (iii) a $1.3 million reduction in consulting expense associated with improving organizational capabilities including the transition to a new electronic medical record ("EMR") system, (iv) $1.0 million reduction in contract staff augmentation, and (iv) $0.9 million reduction in recruiting expense. These decreases in cost were partially offset by (i) $1.5 million increase in employee compensation and benefits as the result of an increase in headcount to support compliance and bolster organizational capabilities, (ii) $1.1 million in bad debt expense, and (iii) $0.3 million in license fees.

Corporate, general and administrative expenses were $54.2 million for the six months ended December 31, 2023, a decrease of $4.8 million, or 8.1%, compared to $59.0 million for the six months ended December 31, 2022. This decrease was primarily due to (i) a $2.7 million reduction in third party ~~costs~~legal expense, (ii) $1.2 million reduction in insurance expense, (iii) $2.9 million reduction in consulting expense associated with ~~implementing our core provider initiatives, assessing our risk-bearing payor capabilities, and strengthening~~improving organizational capabilities including the transition to a new EMR, (iv) $1.2 million reduction in contract staff augmentation, and ~~(iii) a $0.6~~(v) $1.4 million ~~increase~~reduction in ~~software license and maintenance~~recruiting expense. These ~~increases in cost are~~decreases were partially offset by (i) a ~~$0.9 million reduction in bad debt expense and (ii) $4.1 million in executive severance and recruiting recognized during the three months ended December 31, 2021.~~

Corporate, general and administrative expenses were $59.0 million for the six months ended December 31, 2022, an increase of $9.4 million, or 19.0%, compared to $49.6 million for the six months ended December 31, 2021. The increase was primarily due to (i) a $5.0$2.1 million increase in employee compensation and benefits as the result of an increase in headcount, ~~to support compliance and bolster organizational capabilities,~~ (ii) ~~$6.8~~$0.6 million in ~~third party~~bad debt expense, (iii) $0.5 million in consulting costs associated with ~~implementing our core provider initiatives, assessing our risk-bearing payor capabilities,~~Sarbanes-Oxley Act of 2002 compliance and ~~strengthening organizational capabilities including the transition to a new EMR, (iii) $0.8 million in increased legal spend,~~internal audit. and (iv) ~~$1.1~~$1.2 million ~~increase~~ in software license and maintenance ~~expense. These increases in cost were partially offset by (i) a $0.6 million reduction in bad debt~~ expense, ~~and (ii) $4.1 million in executive severance and recruiting recognized during the six months ended December 31, 2021.~~

inclusive of Epic license fees.

Other Income (Expense)

Three Months Ended






Six Months Ended






December 31,

Change

December 31,

Change


2022

2021

$

%

2022

2021

$

%
in thousands

















Interest expense, net

$
(223)

$
(674)

$
451

66.9
%

$
(826)

$
(1,221)

$
395

32.4
%
Other income (expense)

444

28

416

1,485.7
%

480

(465)

945

203.2
%
Total other expense

$
221

$
(646)

$
867

$
(346)

$
(1,686)

$
1,340


	Three Months Ended December 31,				Change			Six Months Ended December 31,				Change
	2023		2022		$		%	2023		2022		$		%
in thousands
Interest expense, net	$	(935)	$	(223)	$	(712)	319.3%	$	(1,596)	$	(826)	$	(770)	93.2%
Other income	874		444		430		96.8%	1,517		480		1,037		216.0%
Other expense	$	(1,882)	$	—	$	(1,882)	100.0%	$	(1,882)	$	—	$	(1,882)	100.0%
Total other expense	$	(1,943)	$	221	$	(2,164)		$	(1,961)	$	(346)	$	(1,615)

Interest expense, net. Interest expense, net, consists primarily of interest payments on our outstanding borrowings, net of interest income earned on our cash and cash equivalents and restricted cash. Interest expense, net was $0.9 million for the three months ended December 31, 2023, an increase of $0.7 million, or 319.3%, compared to $0.2 million for the three months ended December 31, ~~2022, a decrease of $0.5 million, or 66.9%, compared to $0.7 million for the three months ended December 31, 2021.~~2022. The ~~decrease~~increase was primarily due to interest income of ~~$0.8~~$0.9 million from money market funds offsetting interest expense of ~~$1.1~~$1.8 million for the three months ended December 31, ~~2022.~~2023. Interest expense of $1.1 million was offset by interest income of $0.8 million during the three months ended December 31, ~~2021 was negligible.~~

2022.

Interest expense, net was $1.6 million for the six months ended December 31, 2023, an increase of $0.8 million, or 93.2%, compared to $0.8 million for the six months ended December 31, ~~2022, a decrease of $0.4 million, or 32.4%, compared to $1.2 million for the six months ended December 31, 2021. The decrease was primarily~~2022. This increase is due to interest expense of $3.6 million offset by interest income of ~~$1.2~~$2.0 million from money market ~~funds offsetting interest expense of $2.1 million~~accounts during the six months ended December 31, ~~2022. Interest income during~~2023. During the six months ended December 31, ~~2021~~2022, interest expense of $2.1 million was ~~negligible. For additional information regarding our outstanding indebtedness, see Note 8, “Long-Term Debt” to our condensed consolidated financial statements.~~

offset by interest income of $1.2 million.

Other income. Other income ~~(expense).~~ ~~Other income (expense)~~ consists primarily of the net proceeds received from the sale of or disposal of property and equipment and unrealized gains and losses related to short-term investments. Other income ~~(expense)~~ for the three months ended December 31, ~~2022~~2023 increased $0.4 million, or ~~1,485.7%~~96.8%, when compared to the three months ended December 31, ~~2021.~~2022. The increase iswas primarily due to dividends received from our short-term investments of $0.6 million for the ~~recognition~~three months ended December 31, 2023 compared to dividends of ~~$0.4~~$0.2 million ~~in unrealized gains related to short-term investments.~~ for the three months ended December 31, 2022.

Table of Contents

Other income ~~(expense)~~ was $1.5 million for the six months ended December 31, 2023, an increase of $1.0 million, or 216.0%, compared to $0.5 million for the six months ended December 31, ~~2022,~~

~~Table~~2022. This increase was primarily due to dividends received of ~~Contents~~

~~an increase of $1.0~~$1.2 million ~~or 203.2%,~~during the six months ended December 31, 2023 compared to ~~a loss~~dividends of ~~$0.5~~$0.2 million for the six months ended December 31, ~~2021. The~~2022.

Other expense. Other expense was $1.9 million for the three and six months endedDecember 31, 2023, an increase ~~is due~~of $1.9 million, or 100.0%, compared to zero for the ~~recognition of unrealized gains on short-term investments of $0.4 million during the~~three and six months ended December 31, ~~2022~~2022. Subsequent to December 31, 2023, we noted indicators of impairment in ~~addition to~~our minority equity investment of Jetdoc. We determined that indicators were present as of the ~~recognition~~reporting date, and recognized impairment losses of ~~a loss on disposal of assets of $0.5~~$1.9 million during the three and six months ended December 31, ~~2021 related to~~2023. No observable price changes or impairments were recorded during the ~~write off of certain assets in conjunction with a move to a new facility at our Roanoke, Virginia center.~~

three and six months ended December 31, 2022.

Provision for Income Taxes

The Company and its subsidiaries calculate federal and state income taxes currently payable and for deferred income taxes arising from temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured pursuant to enacted tax laws and rates applicable to periods in which those temporary differences are expected to be recovered or settled. The impact on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the date of enactment. The members of ~~SH1~~InnovAge Senior Housing Thornton, LLC ("SH1") and InnovAge Sacramento have elected to be taxed as partnerships, and no provision for income taxes for SH1 or InnovAge Sacramento is included in these condensed consolidated financial statements.

A valuation allowance is provided to the extent that it is more likely than not that deferred tax assets will not be realized. Tax benefits from uncertain tax positions are recognized when it is more likely than not that the position will be sustained upon examination based on the technical merits of the position. The amount recognized is measured as the largest amount of benefit that has a greater than 50% likelihood of being realized upon settlement. The Company recognizes interest and penalty expense associated with uncertain tax positions as a component of provision for income taxes.

During the three months ended December 31, ~~2022~~2023 and ~~2021,~~2022, we reported ~~benefit for income taxes of $2.9 million and a~~ provision for income taxes of ~~$1.2~~$0.1 million and benefit of $2.9 million, respectively. During the six months ended December 31, ~~2022~~2023 and ~~2021,~~2022, we reported ~~benefit for income taxes of $6.4 million and~~ a provision for income taxes of ~~$4.2~~$0.3 million and benefit of $(6.4) million, respectively. The decrease of ~~$10.6~~$6.7 million is primarily due (i) our pretax book loss recognized during the six months ended December 31, ~~2022,~~2023, as compared to pretax book ~~income~~loss recognized during the six months ended December 31, ~~2021~~2022 and (ii) ~~certain permanent differences between~~ the financial and tax accounting treatment of (a) the Section 162(m) limitation on compensation of five highest paid officers, (b) income from entities not subject to tax, and (c) disallowed stock options related to profit unit interests.

change in our valuation allowance.

Net Loss Attributable to Noncontrolling Interests.

~~InnovAge Senior Housing Thornton, LLC (“SH1”)~~

SH1 is a Variable Interest Entity (“VIE”). The Company is the primary beneficiary of SH1 and consolidates SH1. The Company is the primary beneficiary of SH1 because it has the power to direct the activities that are most significant to SH1 and has an obligation to absorb losses or the right to receive benefits from SH1. The most significant activity of SH1 is the operation of the housing facility. The Company has provided a subordinated loan to SH1 and has provided a guarantee for the convertible term loan held by SH1. The SH1 interest is reflected within equity as noncontrolling interests. Our share of earnings ~~are~~is recorded in the consolidated ~~statements~~Statements of ~~operations~~Operations and the share of the other noncontrolling interest holders’ earnings are recorded as net loss attributable to noncontrolling interests.

Our share of earnings are recorded in the consolidated statements of operations and the share of the other noncontrolling interest holders’ earnings are recorded as net loss attributable to noncontrolling interests.

Net ~~Income (Loss)~~

Loss

During the six months ended December 31, ~~2022~~2023 and ~~2021,~~2022, we reported net ~~income (loss)~~loss of ~~($24.2 million)~~$14.8 million and ~~$8.7~~$24.2 million, respectively, consisting of (i) ~~income (loss)~~loss from operations of ~~($30.3 million)~~$12.5 million and ~~$14.6~~$30.3 million, respectively, (ii) other expense of ~~$0.3~~$2.0 million and ~~$1.7~~$0.3 million, respectively, and (iii) a ~~benefit~~provision for income taxes of ~~$6.4~~$0.3 million and ~~provision~~benefit of ~~$4.2~~$6.4 million, respectively, each as described above.

~~Table of Contents~~

Key Business Metrics and Non-GAAP Measures

In addition to our GAAP financial information, we review a number of operating and financial metrics, including the following key metrics and non-GAAP measures, to evaluate our business, measure our performance, identify trends affecting our business, formulate business plans and make strategic decisions. We believe these metrics provide additional perspective and insights when analyzing our core operating performance from period to period and evaluating trends in

Table of Contents

historical operating results. These key business metrics and non-GAAP measures should not be considered superior to, or a substitute for, and should be read in conjunction with, the GAAP financial information presented herein. These measures may not be comparable to similarly-titled performance indicators used by other companies.

Six months ended December 31,


2022

2021

dollars in thousands
Key Business Metrics:





Centers

18

18

Census^(a)

6,460

7,050

Total Member Months^(a)

39,210

42,095

Center-level Contribution Margin

$
43,997

$
83,736

Center-level Contribution Margin as a % of revenue

13.0
%

24.0
%

GAAP Measures:

Net income (loss)

$
(24,247)

$
8,730

Net loss margin

(7.2)
%

2.5
%

Non-GAAP Measures:

Adjusted EBITDA^(b)

$
(5,768)

$
32,962

Adjusted EBITDA Margin^(b)

(1.7)
%

9.5
%


	Six months ended December 31,
	2023			2022
	dollars in thousands
Key Business Metrics:
Centers(a)	18			18
Census(b)	6,780			6,460
Total Member Months(b)	39,670			39,210

Center-level Contribution Margin	$	61,490		$	43,997
Center-level Contribution Margin as a % of revenue	16.6		%	13.0		%

GAAP Measures:
Net income (loss)	$	(14,783)		$	(24,247)
Net loss margin	(4.0)		%	(7.2)		%

Non-GAAP Measures:
Adjusted EBITDA(c)	$	9,997		$	(5,768)
Adjusted EBITDA Margin(c)	2.7		%	(1.7)		%

________________________

(a)During the second quarter ended December 31, 2023, the Company acquired two PACE programs in California from ConcertoCare, one of which is operational. With the addition of the operational ConcertoCare PACE program, the Company operated 18 PACE centers as of December 31, 2023. During the third quarter ended March 31, 2023, the Company consolidated its Germantown LIFE center with its Allegheny and Henry Avenue LIFE centers in Pennsylvania.

~~(a)~~

~~Amounts are approximate.~~

~~(b)~~

Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures. For a definition and reconciliation of these non-GAAP measures to the most closely comparable GAAP measures for the period indicated, see below under “Adjusted EBITDA and Adjusted EBITDA Margin.”

(b)

Amounts are approximate due to rounding.

(c)Adjusted EBITDA and Adjusted EBITDA margin are non-GAAP measures. For a definition and reconciliation of these non-GAAP measures to the most closely comparable GAAP measures for the period indicated, see below under “Adjusted EBITDA and Adjusted EBITDA Margin.”

Centers

We define our centers as those centers open for business and attending to participants at the end of a particular period.

Census

Our census is comprised of our capitated participants for whom we are financially responsible for their total healthcare costs.

~~Table of Contents~~

Total Member Months

We define Total Member Months as the total number of participants multiplied by the number of months within a year in which each participant was enrolled in our program. We believe this is a useful metric as it more precisely tracks the number of participants we serve throughout the year.

Center-level Contribution Margin

The Company's management uses Center-level Contribution Margin as the measure for assessing performance of its operating segments. We define Center-level Contribution Margin as total revenues less external provider costs and cost of care, excluding depreciation and amortization, which includes all medical and pharmacy costs. For purposes of evaluating Center-level Contribution Margin on a center-by-center basis, we do not allocate our sales and marketing ~~expense~~expenses or corporate, general and administrative expenses across our centers. Center-level Contribution Margin was ~~$44.0~~$61.5 million and ~~$83.7~~

Table of Contents

$44.0 million for the six months ended December 31, 2023 and 2022, respectively. The increase in Center-level Contribution Margin for the six months ended December 31, 2023 was primarily due to a 9.7% increase in total revenue, offset by a 5.6% increase in external provider costs during the same period. For more information relating to Center-level Contribution Margin, see Note 14 “Segment Reporting” to our consolidated financial statements. A reconciliation of Center-level Contribution Margin to loss before income taxes, the most directly comparable GAAP measure, for each of the periods is as follows:



	Six Months Ended December 31, 2023							Six Months Ended December 31, 2022
(In thousands)	PACE		All other		Totals			PACE		All other(1)		Totals
Capitation revenue	$	370,734	$	—	$	370,734		$	338,071	$	—	$	338,071
Other service revenue	153		495		648			176		427		603
Total revenues	370,887		495		371,382			338,247		427		338,674
External provider costs	200,322		—		200,322			189,744		—		189,744
Cost of care, excluding depreciation and amortization	109,267		303		109,570			104,595		338		104,933
Center-Level Contribution Margin	61,298		192		61,490			43,908		89		43,997
Overhead costs(a)	65,425		9		65,434			67,107		79		67,186
Depreciation and amortization	8,334		225		8,559			6,881		214		7,095
Interest expense, net	1,506		90		1,596			735		91		826
Other income	(1,517)		—		(1,517)			(480)		—		(480)
Other expense	1,882		—		1,882			—		—		—
Loss Before Income Taxes	$	(14,332)	$	(132)	$	(14,464)		$	(30,335)	$	(295)	$	(30,630)
Loss Before Income Taxes as a % of revenue					(3.9)		%					(9.0)		%
Center- Level Contribution Margin as a % of revenue					16.6		%					13.0		%

(a)Overhead consists of the sales and ~~2021, respectively.~~

marketing and corporate, general and administrative financial statement line items.

Adjusted EBITDA and Adjusted EBITDA Margin

We define Adjusted EBITDA as net income (loss) adjusted for interest expense, depreciation and amortization, and provision (benefit) for income tax as well as addbacks for non-recurring expenses or exceptional items, including charges relating to management equity compensation, ~~class action~~ litigation costs and settlements, M&A ~~transaction~~ and ~~integration,~~de novo center development, business optimization, ~~and~~ electronic medical record ~~(“EMR”~~("EMR") ~~implementation.~~implementation and loss on minority equity interest investment. Adjusted EBITDA margin is Adjusted EBITDA expressed as a percentage of our total ~~revenue less any exceptional, one time revenue items.~~revenue. For the six months ended December 31, ~~2022~~2023 and ~~2021,~~2022, net loss was ~~$24.2~~$14.8 million and ~~net income was $8.7~~$24.2 million, respectively, representing a year-over-year decrease of ~~377.7%~~39.0%. Adjusted EBITDA was $10.0 million and ($5.8 million) ~~and $33.0 million,~~, for the six months ended December 31, ~~2022~~2023 and ~~2021,~~2022, respectively, representing a year-over-year ~~decrease~~increase of ~~117.5%~~273.3%. For the six months ended December 31, ~~2022,~~2023, net loss margin was ~~7.2%~~4.0%, as compared to net ~~income~~loss margin of ~~2.5%~~7.2% for the six months ended December 31, ~~2021.~~2022. For the six months ended December 31, ~~2022,~~2023, our Adjusted EBITDA margin was ~~negative 1.7%~~2.7%, as compared to our Adjusted EBITDA margin for the six months ended December 31, ~~2021~~2022 of ~~9.5%~~negative 1.7%. The ~~decrease~~increase in Adjusted EBITDA and Adjusted EBITDA margin is primarily from (i) increased capitation rates and (ii) lower corporate, general and administrative costs partially offset by, (i) increased center-level headcount and wage rates associated with a competitive labor market, and (ii) increased housing utilization and ~~rates~~unit cost as mandated by the ~~states, and (iii) higher corporate, general, and administrative expenses, primarily attributable to increased headcount to support compliance and to bolster our organizational capabilities.~~

states.

Adjusted EBITDA and Adjusted EBITDA margin are supplemental measures of operating performance monitored by management that are not defined under GAAP and that do not represent, and should not be considered as, an alternative to net income (loss) and net income (loss) margin, respectively, as determined by GAAP. We believe that Adjusted EBITDA and Adjusted EBITDA margin are appropriate measures of operating performance because the metrics eliminate the impact of revenue and expenses that do not relate to our ongoing business performance and certain noncash expenses, allowing us

Table of Contents

to more effectively evaluate our core operating performance and trends from period to period. We believe that Adjusted EBITDA and Adjusted EBITDA margin help investors and analysts in comparing our results across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. These non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation from, or as a substitute for, the analysis of other GAAP financial measures, including net income (loss) and net income (loss) margin. In evaluating Adjusted EBITDA, you should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed to imply that our future results will be unaffected by the types of items excluded from the calculation of Adjusted EBITDA. The use of the term Adjusted EBITDA varies from others in our industry.

~~Table of Contents~~

A reconciliation of net loss to Adjusted EBITDA, ~~to net income,~~ the most directly comparable GAAP measure, for each of the periods is as follows:

Three months ended December 31,

Six months ended December 31,


2022

2021

2022

2021

in thousands

Net income (loss)

$
(10,547)

$
1,106

$
(24,247)

$
8,730
Interest expense, net

223

674

826

1,221
Depreciation and amortization

3,662

3,292

7,095

6,585
Provision (benefit) for income tax

(2,912)

1,201

(6,383)

4,197
Stock-based compensation

1,212

783

2,512

1,741
Executive severance and recruitment^(a)

—

4,123

—

4,123
Class action litigation^(b)

1,282

45

1,238

45
M&A and de novo development^(c)

336

513

622

840
Business optimization^(d)

2,846

2,671

10,035

4,788
EMR implementation^(e)

1,944

342

2,534

692
Adjusted EBITDA

$
(1,954)

$
14,750

$
(5,768)

$
32,962


	Three months ended December 31,				Six months ended December 31,
	2023		2022		2023		2022


Net loss	$	(3,821)	$	(10,547)	$	(14,783)	$	(24,247)
Interest expense, net	935		223		1,596		826
Depreciation and amortization	4,290		3,662		8,559		7,095
Provision (benefit) for income tax	93		(2,912)		319		(6,383)
Stock-based compensation	1,766		1,212		3,589		2,512
Litigation costs and settlement(a)	198		1,282		1,905		1,238
M&A and de novo center development(b)	284		336		693		622
Business optimization(c)	774		2,846		2,933		10,035
EMR implementation(d)	1,370		1,944		3,304		2,534
Loss on minority equity interest(e)	$	1,882	$	—	$	1,882	$	—
Adjusted EBITDA	$	7,771	$	(1,954)	$	9,997	$	(5,768)

________________________

(a)Reflects charges/(credits) related to litigation by stockholders, litigation related to de novo center development, and civil investigative demands. Refer to Note 9, "Commitments and Contingencies" to our condensed consolidated financial statements for more information regarding litigation by stockholders and civil investigative demands. Costs reflected consist of litigation costs considered one-time in nature and outside of the ordinary course of business based on the following considerations which we assess regularly: (i) the frequency of similar cases that have been brought to date, or are expected to be brought within two years, (ii) complexity of the case, (iii) nature of the remedies sought, (iv) litigation posture of the Company, (v) counterparty involved, and (vi) the Company's overall litigation strategy.

(b)Reflects charges related to M&A transaction and integrations, and de novo center developments.

(c)Reflects charges related to business optimization initiatives. Such charges related to one-time investments in projects designed to enhance our technology and compliance systems, improve and support the efficiency and effectiveness of our operations, and third party support to address efforts to remediate deficiencies in audits. For the three months ended December 31, 2023 this includes (i) $0.3 million of costs associated with third party consultants as we implement our core provider initiatives, assess our risk-bearing payor capabilities, and strengthen our enterprise capabilities (ii) $0.3 million of costs related to severance and other organizational costs and (iii) $0.2 million related to other non-recurring charges. For the three months ended December 31, 2022 this includes (i) $0.5 million related to consultants and contractors performing audit and other related services at sanctioned centers, (ii) $0.8 million of costs associated with third party consultants as we implement our core provider initiatives, assess our risk-bearing capabilities, and strengthen our enterprise capabilities and (iii) $0.1 million for related to other non-recurring projects aimed at reducing costs and improving efficiencies. For the six months ended December 31, 2023 this includes (i) $2.1 million of costs associated with third party consultants as we implement our core provider initiatives, assess our risk-bearing payor capabilities, and strengthen our enterprise capabilities (ii) $0.3 million of costs related to severance and other organizational costs and (iii) $0.5 million related to charges for technology improvements, environmental, sustainability, and governance reporting, and other non-recurring charges. For the six months ended December 31, 2022 this includes (i) $1.2 million related to consultants and contractors performing audit and other related services at sanctioned centers, (ii) $5.1 million of costs associated with third party consultants as we implement our core provider initiatives, assess our risk-bearing payor capabilities, and strengthen our enterprise capabilities, and (iii) $0.7 million related to other non-recurring projects aimed at reducing costs and improving efficiencies.

(d)Reflects non-recurring expenses relating to the implementation of a new EMR vendor.

(e)Reflects impairment charges related to our minority equity interest in Jetdoc, Inc.

~~(a)~~

~~Reflects charges related to executive severance and recruiting.~~

~~(b)~~

~~Reflects charges/(credits) related to litigation by stockholders.~~

~~(c)~~

~~Reflects charges related to M&A transaction and integrations, and de novo center developments.~~

~~(d)~~

Reflects charges related to business optimization initiatives. Such charges related to one-time investments in projects designed to enhance our technology and compliance systems, improve and support the efficiency and effectiveness of our operations, and third party support to address efforts to remediate deficiencies in audits. For the three months ended December 31, 2022 this includes (i) $0.5 million related to consultants and contractors performing audit and other related services at sanctioned centers, (ii) $1.4 million of charges related to government investigations, (iii) $0.8 million of costs associated with third party consultants as we implement our core provider initiatives, assess our risk-bearing payor capabilities, and strengthen our enterprise capabilities, and (iv) $0.1 million related to other non-recurring projects aimed at reducing costs and improving efficiencies. For the six months ended December 31, 2022 this includes (i) $1.2 million related to consultants and contractors performing audit and other related services at sanctioned centers, (ii) $3.0 million of charges related to government investigations, (iii) $5.1 million of costs associated with third party consultants as we implement our core provider initiatives, assess our risk-bearing payor capabilities, and strengthen our enterprise capabilities, and (iv) $0.7 million related to other non-recurring projects aimed at reducing costs and improving efficiencies..

~~(e)~~

~~Reflects non-recurring expenses relating to the implementation of a new electronic medical record (“EMR”) vendor.~~

Table of Contents

Liquidity and Capital Resources

General

To date, we have financed our operations principally through cash flows from operations and through borrowings under our credit facilities, and from the sale of common stock in our IPO that occurred in March 2021. As of December 31, ~~2022,~~2023, we had cash and cash equivalents of ~~$99.5 million.~~$54.1 million, a decrease of $73.1 million from June 30, 2023. The decrease in cash and cash equivalents was primarily due to a payment of $23.9 million for the acquisition of the ConcertoCare PACE centers during the second quarter of fiscal year 2024 and timing of cash receipts for services provided. Our cash and cash equivalents primarily consist of highly liquid investments in demand deposit accounts and cash.

Our capital resources are generally used to fund (i) debt service requirements, the majority of which relate to the quarterly principal payments of the Term Loan Facility (as defined in Note 8, ~~“Long Term~~“Long-Term Debt” to the condensed consolidated financial statements) due 2026, (ii) ~~capital~~finance and operating lease obligations, which are generally paid on a monthly basis and include maturities through ~~2025~~2028 and 2032, respectively, (iii) the operations of our business, including special projects such as our transition to a new EMR vendor, with respect to which we ~~expect to incur~~incurred non-recurring implementation costs over the ~~next six~~last three months, and expect to incur ongoing costs through ~~2026,~~2024 and beyond, and third party support to address remediation efforts, ~~and~~ (iv) income tax payments, which are generally due on a quarterly and annual ~~basis.~~basis, and (v) capital additions, which included costs relating to the acquisition of the ConcertoCare PACE centers that took place during the second quarter of fiscal year 2024, and the development of de novo centers, including those in Florida and California. We also ~~will~~invest and for the foreseeable future expect to continue investing in the effective implementation of post-sanction corrective remediation plans (CAPs) and other corrective initiatives as a result of deficiencies found during audits at some of our centers, and our ability to continually provide necessary and quality services to our participants. ~~We also have and expect to continue using capital resources for capital additions, which include costs relating to the development of de novo centers.~~ Collectively, these obligations are expected to represent a significant liquidity requirement of our Company on both a short-term (next 12 months) and long-term (beyond 12 months) basis.

~~Our cash obligations consist of repayments of long-term debt and obligations under operating and finance leases.~~

As of December 31, ~~2022,~~2023, we had ~~$71.7~~$67.9 million of long-term debt outstanding. As of December 31, ~~2022,~~2023, we had future minimum operating lease payments under non-cancellable leases through the year 2032 of ~~$29.4~~$37.5 million. We also had non-cancellable finance lease agreements with third parties through the year ~~2027~~2028 with future minimum payments of ~~$15.2~~$18.3 million. For additional information, see Note 7, “Leases”, Note 8, ~~“Long Term~~“Long-Term Debt”, and Note 9, “Commitments and Contingencies” in our condensed consolidated financial statements.

We believe that our cash and cash equivalents and our cash flows from operations, available funds, and access to financing sources, including our 2021 Credit Agreement and Revolving Credit Facility (each discussed and defined below), will be sufficient to fund our operating and capital needs for the next 12 months and beyond. We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Our actual results could vary because of, and our future capital requirements will depend on, many factors, including our growth rate, our ability to retain and grow the number of PACE participants, ~~subject to our ability to effectively remediate deficiencies identified in our Sacramento center~~ and the expansion of sales and marketing ~~activities.~~activities and other costs of operating the business. We may in the future enter into arrangements to acquire or invest in complementary businesses, services and technologies. We may be required to seek additional equity or debt financing. In the event that additional financing is required from outside sources, we may not be able to raise it on terms acceptable to us or at all. If we are unable to raise additional capital when desired, or if we cannot expand our operations or otherwise capitalize on our business opportunities because we lack sufficient capital, our business, results of operations, and financial condition would be adversely affected.

~~The~~

On March 8, 2021, the Company entered into a credit agreement (as amended, the "2021 Credit ~~Agreement~~Agreement") that consists of a senior secured term loan (the “Term Loan Facility”) of $75.0 million principal amount and a revolving credit facility (the “Revolving Credit Facility”) of $100.0 million maximum borrowing capacity. The borrowing capacity under the Revolving Credit Facility is subject (i) any issued amounts under our letters of credit and (ii) applicable covenant compliance restrictions and any other conditions precedent to borrowing. Principal on the Term Loan Facility is paid each calendar quarter in an amount equal to 1.25% of the initial term loan on closing date.

~~Any outstanding~~

~~Table of Contents~~

remaining borrowing capacity under the Revolving Credit Facility. As of December 31, ~~2022,~~2023, we also had $2.3 million principal amount outstanding under our convertible term loan. Monthly principal and interest payments for the convertible

Table of Contents

term loan are approximately $0.02 million, and the loan bears interest at an annual rate of 6.68%. The remaining principal balance is due upon maturity, which is August 20, 2030.

For more information about our debt, see Note 8 “Long-Term Debt” to our condensed consolidated financial statements.

We currently intend to retain all available funds and any future earnings to fund the development and growth of our business.

Condensed Consolidated Statements of Cash Flows

Our consolidated statements of cash flows for the six months ended December 31, ~~2022~~2023 and ~~2021~~2022 are summarized as follows:

Six months ended December 31,



2022

2021

$ Change
in thousands


Net cash provided (used) by operating activities

$
(21,990)

$
31,577

$
(53,567)
Net cash used in investing activities

(59,632)

(13,681)

(45,951)
Net cash used in financing activities

(3,347)

(3,048)

(299)
Net change in cash, cash equivalents and restricted cash

$
(84,969)

$
14,848

$
(99,817)


	Six months ended December 31,
	2023		2022		$ Change
in thousands
Net cash used by operating activities	$	(42,279)	$	(21,990)	$	(20,289)
Net cash used in investing activities	(26,252)		(59,632)		33,380
Net cash used in financing activities	(4,638)		(3,347)		(1,291)
Net change in cash, cash equivalents and restricted cash	$	(73,169)	$	(84,969)	$	11,800

Operating Activities. The change in net cash provided (used) by operating activities was primarily due to the net effect of (i) net loss of ~~$24.2~~$14.8 million in the current year period compared to a net ~~income~~loss of ~~$8.7~~$24.2 million in the prior year period, as described further above, ~~and~~ (ii) ~~a net decrease~~an increase in ~~working capital~~accounts receivable primarily attributable to the timing of receipt of payments for ~~operating leases~~certain Medicaid receivables, and ~~reported and estimated claims.~~(iii) impacts of deferred revenue due to the timing of payments received during prior year.

Investing Activities. Investing activities were made up of approximately ~~$14.6~~$23.9 million payment for the acquisition of two PACE programs from ConcertoCare, $4.2 million in purchases of property and equipment and ~~$45.0~~$1.2 million for ~~purchases~~reinvested dividends of short-term ~~investments.~~investments, consisting primarily of managed income funds invested in investment grade short-term fixed and floating rate debt securities aimed at creating income while maintaining low volatility on principal. Our investment in managed income funds regularly pay dividends which are reinvested into the funds.

Financing activities. The increase in net cash used in financing activities was primarily due to an increase in taxes paid related to net share settlements of stock-based compensation awards of $0.6 million and an increase in principal payments on finance ~~leases.~~leases of $0.7 million.

Emerging Growth Company and Smaller Reporting Company

We qualify as an “emerging growth company” pursuant to the provisions of the Jumpstart Our Business Startups (“JOBS”) Act and a “smaller reporting company” as defined by the Exchange Act. For as long as we are an “emerging growth company” or a “smaller reporting company,” we may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not “emerging growth companies” or “smaller reporting companies,” including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes-Oxley Act, only being required to present two years of audited financial statements, plus unaudited condensed consolidated financial statements for applicable interim periods and the related discussion in the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” reduced disclosure obligations regarding executive compensation in our periodic reports, proxy statements and registration statements, exemptions from the requirements of holding non-binding advisory “say-on-pay” votes on executive compensation and stockholder advisory votes on golden parachute compensation.

In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We intend to take advantage of the longer phase-in periods for the adoption of new or revised financial accounting standards under the JOBS Act until we are no longer an emerging

~~Table of Contents~~

growth company. Our election to use the phase-in periods permitted by this election may make it difficult to compare our

Table of Contents

financial statements to those of non-emerging growth companies and other emerging growth companies that have opted out of the longer phase-in periods permitted under the JOBS Act and who will comply with new or revised financial accounting standards. If we were to subsequently elect instead to comply with public company effective dates, such election would be irrevocable pursuant to the JOBS Act.

Critical Accounting Estimates

The discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of these financial statements requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from these estimates under different assumptions or conditions, impacting our reported results of operations and financial condition.

Certain accounting estimates involve significant judgments and assumptions by management, which have a material impact on the carrying value of assets and liabilities and the recognition of income and expenses. We consider these accounting estimates to be critical accounting estimates. The estimates and assumptions used by management are based on historical experience and other factors, which are believed to be reasonable under the circumstances.

For a description of our estimates regarding our critical accounting estimates, see “Critical Accounting Estimates” in the ~~2022~~2023 10-K. With the exception of the adoption of ASC 842 – Leases, as more thoroughly described in Note 7 “Leases”, there have been no significant changes in our critical accounting policies, estimates, or methodologies to our condensed consolidated financial statements.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of exposure due to potential changes in inflation or interest rates. We do not hold financial instruments for trading purposes.

Interest rate risk

As of December 31, ~~2022,~~2023, we had total outstanding debt of ~~$69.4~~$65.6 million in principal amount under the Term Loan Facility, $2.3 million under the convertible term loan, and no outstanding debt under the Revolving Credit Facility (each as defined in Note 8, ~~“Long Term~~“Long-Term Debt” to our condensed consolidated financial statements). As of June 30, ~~2022,~~2023, we had total outstanding debt of ~~$71.3~~$67.5 million in principal amount under the Term Loan Facility and $2.3 million under the ~~Convertible Term Loan.~~convertible term loan. As of December 31, ~~2022,~~2023, the interest rate on the Term Loan Facility was ~~6.14%~~7.30%.

We had cash and cash equivalents of ~~$99.5~~$54.1 million and ~~$184.4~~$127.2 million as of December 31, ~~2022~~2023 and June 30, ~~2022,~~2023, respectively, which are deposited with high credit quality financial institutions and are primarily in demand deposit accounts.

Our cash and cash equivalents and interest payments in respect of our debt are subject to market risk due to changes in interest rates. We do not believe that an increase or decrease in interest rates of 100 basis points would have a material effect on our business, financial condition or results of operations.

We had short-term investments of $44.7 million and $46.2 million as of December 31, 2023 and June 30, 2023, respectively, which are primarily invested in managed income funds managed by major financial institutions. The funds mainly invest in investment grade, U.S. denominated short-term fixed and floating rate debt securities. Securities are subject to market risk and sensitive to changes in interest rates. While the instruments held by the funds are generally less sensitive to interest rate changes than instruments with longer maturities due to their short-term nature, the funds may face a heightened level of interest rate risk due to changes in monetary policy. During periods when interest rates are low or negative, the funds yields, and total returns may also be low, or the funds may be unable to maintain positive returns. We do not believe that an increase or decrease in interest rates of 100 basis points would have a material effect on these short-term investments.

Based on our analysis of the periods presented, we believe that inflation has not had a material effect on our operating results. There can be no assurance that future inflation will not have an adverse impact on our operating results and financial condition.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our management, including the Chief Executive Officer and Chief Financial Officer, we have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Report. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that ~~these~~our disclosure controls and procedures were effective as of December 31, ~~2022.~~

2023.

Changes ~~to our~~in Internal Controls over Financial Reporting

There have been no changes in internal control over financial reporting during the quarter ended December 31, ~~2022~~2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

For information regarding our material pending legal proceedings, refer to Note 9 “Commitments and Contingencies” to our Condensed Consolidated Financial Statements located in Item 1 of Part I of this Quarterly Report on Form 10-Q.

Item 1.A Risk Factors

~~There~~Except as set forth below, there have been no material changes to the risk factors previously disclosed in our ~~2022~~2023 10-K.

Labor relations matters could have a material adverse effect on our business, reputation, prospects, results of operations and financial condition.

On October 27, 2023, following a demand from a labor union for the Company to recognize it as the collective bargaining representative of the nurses and certified nurse assistants in our Pennsylvania centers, we filed a petition with the National Labor Relations Board to conduct two elections. The National Labor Relations Board conducted the elections on December 6, 2024, at which the nurses and certified nurse assistants in our Pennsylvania centers voted to unionize. These employees represent approximately 1% of our total workforce. Even though we are currently unaware of other unionization efforts, it is possible that additional employees in our Pennsylvania centers or in other geographies may follow. As we negotiate collective bargaining agreements for the two new bargaining units at the Pennsylvania centers, and any other units that may organize in the future, employees may threaten and/or engage in work stoppages and strikes, and our labor costs may continue to increase as a result. The unavailability of staff, or the inability of the Company to control labor costs related to these matters and future efforts to unionize, could have a material adverse effect on our business, reputation, prospects, results of operations and financial condition.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Item 3. Defaults Upon Senior Securities

Item 4. Mine Safety Disclosures

Item 5. Other Information

~~None.~~

Table of Contents

Item 6. Exhibits

The following is a list of all exhibits filed or furnished as part of this report:

EXHIBIT INDEX


Exhibit No.		Description
~~Exhibit~~ ~~No.~~		~~Description~~
3.1
~~3.1~~	Second Amended and Restated Certificate of Incorporation of InnovAge Holding Corp., filed March 3, 2021 (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed with the SEC on March 8, 2021).

3.2			Amended and Restated Bylaws of InnovAge Holding Corp., effective March 3, 2021 (incorporated by reference to Exhibit 3.2 to the Company’s Current Report on Form 8-K filed with the SEC on March 8, 2021).

10.1		Class B Unit Award Agreement, dated December 18, 2023, by and between TCO Group Holdings, L.P. and Nicole D'Amato (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on December 19, 2023).

31.1			Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2			Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1†			Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2†			Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS			Inline XBRL Instance Document (the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)

101.SCH			Inline XBRL Taxonomy Extension Schema Document

101.CAL			Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF			Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB			Inline XBRL Taxonomy Extension Label Linkbase Document

104			Cover Page Interactive Data File (formatted in Inline XBRL and contained in Exhibit 101)

________________________

†The certifications furnished in Exhibit 32.1 and Exhibit 32.2 hereto are deemed “furnished” with this Quarterly Report on Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.

†

The certifications furnished in Exhibit 32.1 and Exhibit 32.2 hereto are deemed “furnished” with this Quarterly Report on Form 10-Q and will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, except to the extent that the registrant specifically incorporates it by reference.

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, duly authorized.


					INNOVAGE HOLDING CORP.

Date: February 6, 2024			By:	/s/ Benjamin C. Adams
~~Date: February 7, 2023~~			Name:	~~By:~~	~~/s/ Barbara Gutierrez~~ Benjamin C. Adams
			Title:	~~Name:~~	~~Barbara Gutierrez~~
	~~Title:~~	Chief Financial Officer
		(Duly Authorized Officer and Principal Financial and Accounting Officer)


Delaware		81-0710819
~~Delaware~~		~~81-0710819~~
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification Number)

8950 E. Lowry Boulevard Denver,, CO (Address of Principal Executive Offices)		80230 (Zip Code)


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	INNV	The Nasdaq Stock Market LLC (Nasdaq Global Select Market)

		~~Page~~
					Page

Part I					Financial Information

Item 1.					Financial Statements (Unaudited)	5

						Condensed Consolidated Balance Sheets as of December 31 ~~2022~~, 2023 (Unaudited) and June 30, ~~2022~~2023	5

						Condensed Consolidated Statements of Operations for the three and six months ended December 31 , 2023 and 2022 ~~and 2021~~ (Unaudited)	6

						Condensed Consolidated Statements of Stockholders’ Equity for the three and six months ended December 31 , 2023 and 2022 ~~and 2021~~ (Unaudited)	7

						Condensed Consolidated Statements of Cash Flows for the six months ended December 31 , 2023 and 2022 ~~and 2021~~ (Unaudited)	8			9

						Notes to Condensed Consolidated Financial Statements as of December 31 ~~2022~~, 2023 (Unaudited)	9			10

Item 2.					Management’s Discussion and Analysis of Financial Condition and Results of Operations	27			29

Item 3.					Quantitative and Qualitative Disclosures About Market Risk	42			43

Item 4.					Controls and Procedures	43			44

Part II		Other Information			45

~~Part II~~Item 1.		Legal Proceedings			~~Other Information~~45			44

Item 1A.		Risk Factors			45
~~Item 1.~~					~~Legal Proceedings~~			44

~~Item 1A.~~	~~Risk Factors~~	44

Item 2.			Unregistered Sales of Equity Securities and Use of Proceeds	44			45

Item 3.					Defaults Upon Senior Securities	44			45

Item 4.					Mine Safety Disclosures	44			45

Item 5.		Other Information			45

Item 5.6.		Exhibits			~~Other Information~~46			44

Exhibit Index					46
~~Item 6.~~					~~Exhibits~~			45
Signatures					47
~~Exhibit Index~~		45

~~Signatures~~		46


	December 31,		June 30,
	2022		2022
Assets
Current Assets
Cash and cash equivalents	$	99,460	$	184,429
Short-term investments		45,424		—
Restricted cash		17		17
Accounts receivable, net of allowance ($4,202 – December 31, 2022 and $3,403 – June 30, 2022)		38,643		35,907
Prepaid expenses		12,212		13,842
Income tax receivable		3,733		6,761
Total current assets		199,489		240,956
Noncurrent Assets
Property and equipment, net		185,774		176,260
Operating lease assets		22,223		—
Investments		5,493		5,493
Deposits and other		3,391		2,812
Goodwill		124,217		124,217
Other intangible assets, net		5,528		5,858
Total noncurrent assets		346,626		314,640
Total assets	$	546,115	$	555,596
Liabilities and Stockholders' Equity
Current Liabilities
Accounts payable and accrued expenses	$	48,901	$	50,562
Reported and estimated claims		35,115		38,454
Due to Medicaid and Medicare		11,077		9,130
Current portion of long-term debt		3,794		3,793
Current portion of finance lease obligations		3,864		3,368
Current portion of operating lease obligations		3,434		—
Total current liabilities		106,185		105,307
Noncurrent Liabilities
Deferred tax liability, net		11,379		17,761
Finance lease obligations		9,032		9,440
Operating lease obligations		20,034		—
Other noncurrent liabilities		1,182		1,134
Long-term debt, net of debt issuance costs		66,528		68,210
Total liabilities		214,340		201,852
Commitments and Contingencies (See Note 9)
Redeemable Noncontrolling Interests (See Note 4)		14,054		15,278
Stockholders’ Equity
Common stock, $0.001 par value; 500,000,000 authorized as of December 31, 2022 and June 30, 2022; 135,596,225 and 135,532,811 issued shares as of December 31, 2022 and June 30, 2022, respectively		136		136
Additional paid-in capital		329,777		327,499
Retained earnings (deficit)		(18,137)		4,729
Total InnovAge Holding Corp.		311,776		332,364
Noncontrolling interests		5,945		6,102
Total stockholders’ equity		317,721		338,466
Total liabilities and stockholders’ equity	$	546,115	$	555,596


	Three Months Ended December 31,				Six Months Ended December 31,
	2022		2021		2022		2021
Revenues
Capitation revenue	$	167,140	$	174,964	$	338,071	$	347,518
Other service revenue		316		386		603		902
Total revenues		167,456		175,350		338,674		348,420
Expenses
External provider costs		93,507		91,033		189,744		181,045
Cost of care, excluding depreciation and amortization		51,376		42,911		104,933		83,639
Sales and marketing		3,774		6,679		8,187		12,972
Corporate, general and administrative		28,817		28,482		58,999		49,566
Depreciation and amortization		3,662		3,292		7,095		6,585
Total expenses		181,136		172,397		368,958		333,807
Operating Income (Loss)		(13,680)		2,953		(30,284)		14,613

Other Income (Expense)
Interest expense, net		(223)		(674)		(826)		(1,221)
Other income (expense)		444		28		480		(465)
Total other expense		221		(646)		(346)		(1,686)
Income (Loss) Before Income Taxes		(13,459)		2,307		(30,630)		12,927
Provision (Benefit) for Income Taxes		(2,912)		1,201		(6,383)		4,197
Net Income (Loss)		(10,547)		1,106		(24,247)		8,730
Less: net loss attributable to noncontrolling interests		(754)		(217)		(1,381)		(279)
Net Income (Loss) Attributable to InnovAge Holding Corp.	$	(9,793)	$	1,323	$	(22,866)	$	9,009

Weighted-average number of common shares outstanding - basic		135,578,888		135,516,513		135,572,503		135,516,513
Weighted-average number of common shares outstanding - diluted		135,578,888		135,516,513		135,572,503		135,516,513

Net income (loss) per share - basic	$	(0.07)	$	0.01	$	(0.17)	$	0.07
Net income (loss) per share - diluted	$	(0.07)	$	0.01	$	(0.17)	$	0.07


	For the Three Months Ended December 31, 2022
				Additional		Retained				Total		Redeemable
	Capital Stock			Paid-in		Earnings		Noncontrolling		Permanent		Noncontrolling Interests		Net Income
	Shares	Amount		Capital		(Deficit)		Interests		Stockholders' Equity		(Temporary Equity)		(Loss)
Balances, September 30, 2022	135,570,078	$	136	$	328,708	$	(8,344)	$	6,020	$	326,520		14,734
Stock-based compensation	26,147		—		1,069		—		—		1,069		—
Adjustments to redemption value	—		—		—		—		—		—		—
Net loss	—		—		—		(9,793)		(75)		(9,868)		(680)		(10,547)
Balances, December 31, 2022	135,596,225	$	136	$	329,777	$	(18,137)	$	5,945	$	317,721	$	14,054	$

	For the Six Months Ended December 31, 2022
				Additional		Retained				Total		Redeemable
	Capital Stock			Paid-in		Earnings		Noncontrolling		Permanent		Noncontrolling Interests		Net Income
	Shares	Amount		Capital		(Deficit)		Interests		Stockholders' Equity		(Temporary Equity)		(Loss)
Balances, June 30, 2022	135,532,811	$	136	$	327,499	$	4,729	$	6,102	$	338,466		15,278
Stock-based compensation	63,414		—		2,278		—		—		2,278		—
Adjustments to redemption value	—		—		—		—		—		—		—
Net loss	—		—		—		(22,866)		(157)		(23,023)		(1,224)		(24,247)
Balances, December 31, 2022	135,596,225	$	136	$	329,777	$	(18,137)	$	5,945	$	317,721	$	14,054	$


	Estimated
dollars in thousands	Useful Lives	December 31, 2022		June 30, 2022
Land	N/A	$	11,980	$	11,980
Buildings and leasehold improvements	10 - 40 years		122,885		122,076
Software	3 - 5 years		27,532		16,264
Equipment and vehicles	3 - 7 years		49,847		47,546
Construction in progress	N/A		37,091		35,479
			249,335		233,345
Less: accumulated depreciation and amortization			(63,561)		(57,085)
Total property and equipment, net		$	185,774	$	176,260


	December 31,		June 30,
in thousands	2022		2022
Cost method investments	$	4,645	$	4,645
Equity method investments		848		848
Total investments	$	5,493	$	5,493


		2022
										Cash and		Short-
		Amortized		Unrealized		Unrealized		Fair		Cash		term
in thousands		Cost		Gains		Losses		Value		Equivalents		Investments
Cash	$	18,858	$	—	$	—	$	18,858	$	18,858	$	—
Level 1
Money market funds		80,602		—		—		80,602		80,602		—
Mutual funds		45,000		424		—		45,424		—		45,424
Total	$	144,460	$	424	$	—	$	144,884	$	99,460	$	45,424


Component of Lease Balances	Balance Sheet Line Items		Six months ended December 31,
			2022
		in thousands
Assets:
Operating lease assets	Operating lease assets	$	22,223
Finance lease assets	Property and equipment, net		11,153
Total leased assets		$	33,376


Component of Lease Cost	Statements of Operations Line Items		Six months ended December 31,
			2022
		in thousands
Operating lease cost	Cost of care excluding depreciation and amortization and Corporate, general and administrative	$	2,557
Finance lease expense:
Amortization of leased assets	Depreciation and amortization		1,685
Interest on lease liabilities	Interest expense, net		562
Variable lease cost	Cost of care excluding depreciation and amortization and Corporate, general and administrative		—
Short-term lease cost	Cost of care excluding depreciation and amortization and Corporate, general and administrative		17
Total lease expense		$	4,821


	Operating		Finance
in thousands	Lease		Lease		Total
Amount remaining in 2023	$	2,552	$	2,580	$	5,132
2024		4,542		4,263		8,805
2025		4,136		3,480		7,616
2026		4,061		2,456		6,517
2027		3,764		1,760		5,524
Thereafter		10,302		686		10,988
Total lease payments		29,357		15,225		44,582
Less liability accretion / imputed interest		(5,889)		(2,329)		(8,218)
Total lease liabilities		23,468		12,896		36,364
Less: Current lease liabilities		3,434		3,864		7,298
Total long-term lease liabilities	$	20,034	$	9,032	$	29,066


	Number of	Weighted average
Time-based unit awards	units	grant date fair value

Outstanding balance, June 30, 2022	2,158,072	$	1.28
Granted	—	$	—
Forfeited	(49,654)	$	1.28
Vested	(844,081)	$	1.28
Outstanding balance, December 31, 2022	1,264,337	$	1.28


	Number of	Weighted average
Performance-based unit awards	units	grant date fair value

Outstanding balance, June 30, 2022	2,217,865	$	0.57
Granted	—	$	—
Forfeited	(99,307)	$	0.57
Vested	—	$	—
Outstanding balance, December 31, 2022	2,118,558	$	0.57


			Weighted
			average
	Number of		grant-date fair
Restricted stock units - time based	awards		value per share

Outstanding balance, June 30, 2022	476,768	$	9.69
Granted	986,200	$	5.97
Forfeited	(155,741)	$	5.48
Vested	(97,727)	$	4.50
Outstanding balance, December 31, 2022	1,209,500	$	6.41


	2022
Expected volatility		34.5	%
Weighted-average expected life (years) - time vesting units		2.9
Interest rate		1.56	%
Dividend yield		0	%
Weighted-average fair values	$	0.80
Fair value of underlying stock	$	3.70


	Three months ended December 31,				Six months ended December 31,
in thousands, except share values	2022		2021		2022		2021
Net income (loss) attributable to InnovAge Holding Corp.	$	(9,793)	$	1,323	$	(22,866)	$	9,009
Weighted average common shares outstanding (basic)		135,578,888		135,516,513		135,572,503		135,516,513
EPS (basic)	$	(0.07)	$	0.01	$	(0.17)	$	0.07

Dilutive shares		—		—		—		—
Weighted average common shares outstanding (diluted)		135,578,888		135,516,513		135,572,503		135,516,513
EPS (diluted)	$	(0.07)	$	0.01	$	(0.17)	$	0.07


	December 31, 2022						December 31, 2021
(In thousands)	PACE		All other⁽¹⁾		Totals		PACE		All other⁽¹⁾		Totals
Capitation revenue	$	167,140	$	—	$	167,140	$	174,964	$	—	$	174,964
Other service revenue		99		217		316		60		326		386
Total revenues		167,239		217		167,456		175,024		326		175,350
External provider costs		93,507		—		93,507		91,033		—		91,033
Cost of care, excluding depreciation and amortization		51,184		192		51,376		42,478		433		42,911
Center-Level Contribution Margin		22,548		25		22,573		41,513		(107)		41,406
Overhead costs⁽²⁾		32,532		59		32,591		35,160		1		35,161
Depreciation and amortization		3,555		107		3,662		3,185		107		3,292
Interest expense, net		(177)		(46)		(223)		(624)		(50)		(674)
Other expense (income)		444		—		444		29		(1)		28
Income (Loss) Before Income Taxes	$	(13,272)	$	(187)	$	(13,459)	$	2,573	$	(266)	$	2,307


	Three Months Ended				Six Months Ended
	December 31,				December 31,
in thousands	2022		2021		2022		2021
Revenues
Capitation revenue	$	167,140	$	174,964	$	338,071	$	347,518
Other service revenue		316		386		603		902
Total revenues		167,456		175,350		338,674		348,420
Expenses
External provider costs		93,507		91,033		189,744		181,045
Cost of care, excluding depreciation and amortization		51,376		42,911		104,933		83,639
Sales and marketing		3,774		6,679		8,187		12,972
Corporate, general and administrative		28,817		28,482		58,999		49,566
Depreciation and amortization		3,662		3,292		7,095		6,585
Total expenses		181,136		172,397		368,958		333,807
Operating Income (Loss)	$	(13,680)	$	2,953	$	(30,284)	$	14,613

Other Income (Expense)
Interest expense, net		(223)		(674)		(826)		(1,221)
Other income (expense)		444		28		480		(465)
Total other expense		221		(646)		(346)		(1,686)
Income (Loss) Before Income Taxes		(13,459)		2,307		(30,630)		12,927
Provision (Benefit) for Income Taxes		(2,912)		1,201		(6,383)		4,197
Net Income (Loss)	$	(10,547)	$	1,106	$	(24,247)	$	8,730
Less: net loss attributable to noncontrolling interests		(754)		(217)		(1,381)		(279)
Net Income (Loss) Attributable to InnovAge Holding Corp.	$	(9,793)	$	1,323	$	(22,866)	$	9,009